{"study_id": 102464, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical importance of the De Ritis Ratio (aspartate transaminase/alanine transaminase) as a prognostic, diagnostic, and predictive marker in cancer.", "results_summary": "The De Ritis Ratio was strongly associated with prognostic risk factors, could predict disease progression, and improved diagnostics when combined with other biomarkers. It was found to be an accessible, inexpensive, and clinically valuable marker in cancer.", "population_specificity": "Cancer patients (specific type not specified in the abstract).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:37.246308+00:00"}
{"study_id": 102465, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether orlistat treatment improves NAFLD-related factors, including liver enzymes like alanine transaminase, in adolescents with NAFLD.", "results_summary": "Orlistat significantly improved liver enzymes (alanine transaminase and aspartate transaminase), NAFLD activity score, weight, BMI, glucose metabolism, and lipid profiles compared to placebo over 12 weeks, though no significant effect was observed on triglyceride levels.", "population_specificity": "Overweight/obese adolescents with NAFLD (n=53, aged 12-18).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:38.460427+00:00"}
{"study_id": 102466, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between liver severity indices (including alanine aminotransferase levels) and mortality in non-cirrhotic chronic liver disease (CLD) patients with COVID-19.", "results_summary": "The study found that higher alanine aminotransferase levels were associated with mortality in non-cirrhotic CLD patients with COVID-19, along with other liver severity indices like ALBI grade 3 and FIB-4 index \u2265 3.25.", "population_specificity": "Hospitalized patients with non-cirrhotic chronic liver disease (CLD) and COVID-19 (n=231).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:38.540566+00:00"}
{"study_id": 102463, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of SGLT2 inhibitors versus DPP4 inhibitors on liver function, specifically focusing on alanine aminotransferase (ALT) levels, in Japanese patients with type 2 diabetes.", "results_summary": "The study found that SGLT2 inhibitors significantly reduced ALT, FIB-4 index, and GGT levels while increasing albumin compared to DPP4 inhibitors, suggesting potential hepatoprotective benefits, including prevention of liver fibrosis.", "population_specificity": "Japanese patients with type 2 diabetes.", "effective_dosage": "Not specified in the abstract.", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:38.712959+00:00"}
{"study_id": 102469, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of BMS-986,205 (an IDO inhibitor) in combination with nivolumab for advanced HCC, not specifically studying alanine.", "results_summary": "The study reported elevated alanine transaminase (ALT) as a treatment-related adverse event in 3 patients but did not assess alanine's effects directly.", "population_specificity": "Adults with untreated, unresectable/metastatic HCC (Child Pugh A, some with viral hepatitis).", "effective_dosage": "Not applicable (alanine was not administered).", "study_duration": "Not specified for alanine-related effects.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.038858+00:00"}
{"study_id": 102462, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether measuring hepatitis B core-related antigen (HBcrAg) after nucleos(t)ide analog cessation could predict the risk of clinical relapse in chronic hepatitis B patients.", "results_summary": "The study found that dynamic measurement of HBcrAg after treatment cessation was predictive of subsequent clinical relapse, with HBcrAg <1,000 U/mL indicating a lower risk. Time-varying HBcrAg levels were significantly associated with relapse risk.", "population_specificity": "Adults with chronic hepatitis B who discontinued entecavir or tenofovir, excluding those with cirrhosis or malignancy.", "effective_dosage": "Not specified", "study_duration": "Median treatment duration of 36.9 months, with a median post-treatment follow-up of 31.7 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.106765+00:00"}
{"study_id": 102461, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and activity of combining nab-paclitaxel with gemcitabine in pretreated soft tissue sarcoma (STS) patients, including monitoring alanine aminotransferase levels as an adverse event.", "results_summary": "The study found that the combination therapy had manageable toxicity, with a 2.6% incidence of grade \u22653 alanine aminotransferase increase. The regimen showed promising activity in pretreated STS patients, with a 3-month progression-free rate of 56.4%.", "population_specificity": "Pretreated soft tissue sarcoma (STS) patients.", "effective_dosage": "Nab-paclitaxel was given at 150 mg/m\u00b2 (specific frequency not detailed in the abstract).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.275734+00:00"}
{"study_id": 102467, "supplement_id": 863, "safety_score": "75", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of LXI-15029, an mTORC1/2 dual inhibitor, in Chinese patients with advanced malignant solid tumors, with a focus on adverse events including increased alanine aminotransferase.", "results_summary": "LXI-15029 was well tolerated, with the most common treatment-related adverse event being increased alanine aminotransferase (20.8%). The disease control rate was 40.0%, and the median progression-free survival was 29 days.", "population_specificity": "Chinese patients with advanced, unresectable malignant solid tumors who had failed routine therapy or had no standard treatment.", "effective_dosage": "Ascending doses (10, 20, 40, 60, 80, 110, and 150 mg) administered orally twice daily.", "study_duration": "Until disease progression or intolerable adverse events (specific duration not stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:41.777427+00:00"}
{"study_id": 102470, "supplement_id": 863, "safety_score": "80", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of danicopan (ALXN2040), an oral complement factor D inhibitor, as add-on therapy to ravulizumab or eculizumab in patients with PNH and clinically significant extravascular haemolysis.", "results_summary": "Danicopan significantly increased hemoglobin levels at week 12 compared to placebo, with no new safety concerns reported. Adverse events were noted but were generally manageable, with no serious adverse events related to the study drug or deaths.", "population_specificity": "Adults (age \u226518 years) with PNH and clinically significant extravascular haemolysis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:47.098380+00:00"}
{"study_id": 102471, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the consistency of liver function test results, including alanine transaminase, between two analyzers (Architect c8000 and Cobas C501).", "results_summary": "The study found a highly significant correlation (r>0.90) between the results of liver function parameters, including alanine transaminase, obtained from the two analyzers.", "population_specificity": "Patients undergoing liver function tests at Dr. Mohammad Hoesin General Hospital, Palembang, South Sumatra, Indonesia.", "effective_dosage": "Not available", "study_duration": "Sample collection occurred from June to December 2019.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:48.027511+00:00"}
{"study_id": 102474, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy of fecal microbiota transplantation (FMT) in treating type 2 diabetes mellitus (T2DM), including its impact on Alanine Transaminase (ALT) levels.", "results_summary": "The study found that FMT treatment significantly reduced ALT levels in T2DM patients, indicating potential liver function improvement. Combined FMT regimens showed broader metabolic benefits, including reductions in PBG, TG, HOMA-IR, TC, and DBP.", "population_specificity": "Patients with type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:48.362130+00:00"}
{"study_id": 102475, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the impact of zinc supplementation on serum alanine aminotransferase (ALT) concentrations and other metabolic parameters in overweight or obese children with nonalcoholic steatohepatitis (NASH).", "results_summary": "Zinc supplementation significantly reduced serum ALT concentrations and high-sensitivity C-reactive protein while increasing HDL-cholesterol, but had no significant effect on aspartate aminotransferase, liver steatosis severity, or other lipid indices compared to placebo.", "population_specificity": "Overweight or obese children aged 10-18 years with NASH.", "effective_dosage": "30 mg/day of elemental zinc.", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:49.240318+00:00"}
{"study_id": 102472, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether exercise training improves liver fibroinflammation biomarkers, including alanine aminotransferase (ALT), in patients with metabolic dysfunction-associated steatohepatitis without significant body weight loss.", "results_summary": "Exercise training significantly improved ALT levels (53% of participants saw \u226517 IU/L reduction) and CK18 levels compared to standard care, correlating with reduced liver fat and PNPLA3 genotype. The study suggests exercise can improve liver fibroinflammation biomarkers independently of weight loss.", "population_specificity": "Patients with metabolic dysfunction-associated steatohepatitis (MASH).", "effective_dosage": "Not specified (exercise intervention involved moderate-intensity aerobic training).", "study_duration": "20 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:50.169932+00:00"}
{"study_id": 102476, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the normal reference interval for thiamine concentrations in healthy dogs and investigate the prevalence of thiamine deficiency in critically ill dogs with and without sepsis.", "results_summary": "The study established a reference interval for whole-blood thiamine pyrophosphate (TPP) in healthy dogs (70.9-135.3 \u03bcg/L) and found significantly lower TPP concentrations in septic dogs compared to healthy controls, with 27.3% of septic dogs showing thiamine deficiency. No significant differences were found between septic and nonseptic critically ill dogs or between healthy and nonseptic critically ill dogs.", "population_specificity": "109 dogs (40 healthy, 33 septic with tissue hypoperfusion, 36 nonseptic critically ill with tissue hypoperfusion).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:50.265390+00:00"}
{"study_id": 102477, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify important predictors, including alanine aminotransferase, for the prognosis of advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.", "results_summary": "Alanine aminotransferase was identified as one of the six most important predictors for unfavorable prognosis in advanced NPC patients, as determined by the random forest model. The study did not evaluate alanine's direct effects or efficacy as a supplement.", "population_specificity": "Advanced nasopharyngeal carcinoma (stage III-IV) patients treated with intensity-modulated radiotherapy in Meizhou People's Hospital, China.", "effective_dosage": "Not available", "study_duration": "Average follow-up period of 7.16 years (from July 2020 to March 2021).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:51.509133+00:00"}
{"study_id": 102478, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the minimum effective dose of prophylactic acetaminophen to close the ductus arteriosus and assess its safety and tolerability in extremely preterm infants.", "results_summary": "The study found that acetaminophen was effective in closing the ductus arteriosus in 65.5% of cases, with no adverse effects on hepatic function or hemodynamics. No significant changes in alanine aminotransferase values were observed, and the treatment was well tolerated.", "population_specificity": "Extremely preterm infants at 23-26 weeks of gestation.", "effective_dosage": "25 mg/kg loading dose followed by 10 mg/kg every 6 hours.", "study_duration": "5 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:52.612327+00:00"}
{"study_id": 102479, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of various interventions, including GLP-1RAs like exenatide and liraglutide, for treating NAFLD in patients with T2DM, but did not specifically focus on Alanine.", "results_summary": "The study did not assess Alanine; it focused on interventions like exenatide, liraglutide, dapagliflozin, and pioglitazone for NAFLD and T2DM.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:57.696748+00:00"}
{"study_id": 102481, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether remote ischemic preconditioning could reduce ischemia-reperfusion injury in patients with chronic liver disease undergoing hepatectomy.", "results_summary": "Remote ischemic preconditioning did not significantly reduce postoperative transaminase levels or affect clinical outcomes and biomarkers in patients with chronic liver disease.", "population_specificity": "102 patients with chronic liver disease undergoing hepatectomy (median age 69.5 years, 67.7% male).", "effective_dosage": "Not Assessed", "study_duration": "3 cycles of 10-minute ischemia and reperfusion of the upper extremity.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:58.000394+00:00"}
{"study_id": 102482, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the 3-year safety profile of bimekizumab (BKZ) in patients with moderate-to-severe plaque psoriasis, not specifically Alanine.", "results_summary": "The study found that BKZ had a manageable safety profile over 3 years, with common adverse events like nasopharyngitis and oral candidiasis, mostly mild or moderate. No new safety signals emerged with prolonged exposure.", "population_specificity": "Patients with moderate-to-severe plaque psoriasis.", "effective_dosage": "Not specified for Alanine.", "study_duration": "3 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:58.090607+00:00"}
{"study_id": 102480, "supplement_id": 863, "safety_score": "80", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of etranacogene dezaparvovec-drlb (containing a codon-optimized Padua variant of human FIX) in treating congenital hemophilia B.", "results_summary": "The therapy resulted in stable, sustained near-normal to normal FIX levels, significantly reducing bleeding and FIX prophylaxis needs. It was well tolerated, though 17% of patients required corticosteroids for ALT elevation.", "population_specificity": "Patients with congenital hemophilia B (Factor IX deficiency).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:58.133647+00:00"}
{"study_id": 102484, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to characterize changes in alanine concentration and its relationship with organ failure severity in critically ill patients under intermittent versus continuous feeding regimens.", "results_summary": "The study found a logfold decrease in alanine abundance (-0.594) over time, with increasing organ failure severity correlating with changes in alanine levels (p = 0.005). No significant alteration in metabolite patterns, including alanine, was observed between intermittent and continuous feeding.", "population_specificity": "Critically ill patients in intensive care units (ICUs).", "effective_dosage": "Not specified (feeding regimen was 6x/day for intermittent arm).", "study_duration": "10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:00.907857+00:00"}
{"study_id": 102485, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy and safety of stem cell transplantation (SCT) in treating liver cirrhosis, including its effects on alanine aminotransferase (ALT) levels.", "results_summary": "The study found no significant beneficial effects of SCT on ALT levels in patients with liver cirrhosis, though it did show improvements in other clinical outcomes like MELD score and platelet count.", "population_specificity": "Patients with liver cirrhosis.", "effective_dosage": "Not specified.", "study_duration": "Outcomes were assessed at 1 month and 3 months post-intervention.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:01.063893+00:00"}
{"study_id": 102483, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety of inactivated COVID-19 vaccination during the peri-pregnancy period, including monitoring serum alanine transaminase (ALT) levels as a secondary outcome.", "results_summary": "The study found no significant difference in primary adverse outcomes between vaccinated and control groups, but ALT levels were significantly higher in the vaccine group during the first trimester. The sensitivity analysis supported the robustness of these findings.", "population_specificity": "Pregnant women in China receiving pregnancy care between January 1, 2021, and December 31, 2021.", "effective_dosage": "Not specified (inactivated COVID-19 vaccine, details not provided).", "study_duration": "Peri-pregnancy period (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:01.239017+00:00"}
{"study_id": 102486, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate clinical findings, treatment strategies, and outcomes in dogs with hepatic abscessation, including the role of alanine aminotransferase as a diagnostic marker.", "results_summary": "The study found increased alanine aminotransferase levels in 40 of 50 dogs with hepatic abscessation, indicating liver involvement, but did not assess alanine's therapeutic or supplemental effects.", "population_specificity": "Fifty-six client-owned dogs with confirmed hepatic abscessation.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:02.279564+00:00"}
{"study_id": 102490, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To investigate the efficacy and safety of semaglutide in patients with NAFLD.", "results_summary": "Semaglutide increased the likelihood of NASH resolution and improved liver enzymes and liver fat content, while maintaining a well-tolerated safety profile.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:05.462715+00:00"}
{"study_id": 102489, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the antitumor activity and safety of dostarlimab in patients with advanced or recurrent dMMR solid tumors.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with advanced or recurrent dMMR and MSI-H or POLE-altered solid tumors.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:05.655136+00:00"}
{"study_id": 102488, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and adverse events associated with oral antifungals, including potential effects on alanine transaminase levels.", "results_summary": "The study identified potential adverse events related to oral antifungals, including hepatotoxicity and alanine transaminase elevations, and recommended hepatic monitoring.", "population_specificity": "Patients with moderate-severe onychomycosis", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Interactions with cytochrome-p450 enzymes and other drugs were noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:06.597512+00:00"}
{"study_id": 102493, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the hepatic complications associated with AAV vector-based gene therapy, particularly focusing on raised ALT (alanine aminotransferase) levels as a side effect.", "results_summary": "The study highlights that AAV-based gene therapy, while promising for conditions like haemophilia, is associated with hepatic reactions, including elevated ALT and AST levels. The long-term risks and mechanisms of these ALT flares remain undetermined.", "population_specificity": "Patients undergoing liver-directed AAV vector-based gene therapy, particularly for haemophilia A and B.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:11.157851+00:00"}
{"study_id": 102491, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between Dysosmobacter welbionis abundance and metabolic health, including its correlation with alanine aminotransferase (ALT) levels in humans with obesity and diabetes.", "results_summary": "D. welbionis abundance was negatively correlated with ALT levels, suggesting a potential role in liver health. The study also found higher baseline D. welbionis levels in prebiotic responders, indicating a possible link to metabolic health.", "population_specificity": "Human participants with obesity and diabetes (n=106) and mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Metformin treatment influenced D. welbionis abundance but had no direct effect on its growth in vitro.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:11.446834+00:00"}
{"study_id": 102487, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity of QL1604, a monoclonal antibody targeting PD-1, in patients with advanced or metastatic solid tumors.", "results_summary": "QL1604 showed a manageable safety profile with common adverse events including fatigue, anemia, and elevated liver enzymes. Partial responses were observed in 20% of patients, indicating preliminary antitumor activity.", "population_specificity": "Patients with advanced or metastatic solid tumors who failed or had no standard therapies available.", "effective_dosage": "0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg intravenously every 2 weeks (Q2W) or 3 mg/kg Q2W, 3 mg/kg every 3 weeks (Q3W), 10 mg/kg Q2W, and a fixed dose of 200 mg Q3W.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:11.991113+00:00"}
{"study_id": 102494, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of liver dose-volume on changes in liver function tests (LFTs), including alanine aminotransferase (ALT), in patients undergoing right breast radiotherapy.", "results_summary": "The study found a median increase of up to 15% in ALT and other LFTs post-radiotherapy, indicating acute liver damage, even without systemic treatment or risk factors.", "population_specificity": "100 patients (median age 56) treated for right breast cancer across three centers.", "effective_dosage": "Not specified for alanine; radiotherapy dose was 50 Gy in 25 fractions, with a median boost dose of 10 Gy for some patients.", "study_duration": "Follow-up LFTs were assessed in the first two weeks post-radiotherapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:12.265900+00:00"}
{"study_id": 102495, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of seven interventions, including combinations involving Alanine-related outcomes (e.g., normalizing alanine aminotransferase levels), for treating chronic hepatitis D.", "results_summary": "The study found that IFN, IFN + BLV, and IFN + NAs were effective in clearing HDV RNA and normalizing alanine aminotransferase levels, with IFN + BLV showing strong synergistic effects. However, the seven regimens did not significantly improve liver histology.", "population_specificity": "814 patients with chronic hepatitis D across 14 randomized controlled trials.", "effective_dosage": "Not specified", "study_duration": "24 weeks of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:12.948017+00:00"}
{"study_id": 102498, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to identify metabolites, including alanine, that could serve as potential biomarkers for severe traumatic brain injury (sTBI) and examine their effects on metabolic pathways.", "results_summary": "The study found that alanine levels decreased in adults post sTBI, suggesting its involvement in altered metabolic pathways, particularly in amino acid metabolism. However, the study noted significant ambiguity in the literature regarding metabolic profiles due to varying study designs and methodologies.", "population_specificity": "Adults with severe traumatic brain injury (sTBI).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:15.425725+00:00"}
{"study_id": 102496, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of giroctocogene fitelparvovec, an AAV vector-based gene therapy, in increasing endogenous FVIII production in patients with severe hemophilia A, with a focus on monitoring alanine aminotransferase levels as a safety marker.", "results_summary": "The study found that increases in alanine aminotransferase were common but resolved with corticosteroid treatment. The therapy was generally well-tolerated and provided clinically meaningful FVIII activity levels, particularly at the highest dose, with a low rate of bleeding events.", "population_specificity": "Male participants with severe hemophilia A.", "effective_dosage": "Single IV dose of 3 \u00d7 10\u00b9\u00b3 vg/kg (highest dose level).", "study_duration": "Follow-up up to 214 weeks after treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:17.296048+00:00"}
{"study_id": 102499, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the feasibility, efficacy, and safety of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma (HNSCC).", "results_summary": "The study found a 90% completion rate of CCRT and a 90% overall response rate. Adverse events included oral/pharyngeal mucositis (47%), leukocytopenia (20%), and neutropenia (10%), with one case of grade 4 alanine aminotransferase elevation.", "population_specificity": "Adult patients (\u226520 years) with HNSCC who were cisplatin-ineligible due to age (\u226575 years with eGFR \u226540 mL/min) or renal dysfunction (<75 years with eGFR 30-60 mL/min).", "effective_dosage": "Carboplatin administered weekly (AUC = 2.0) for up to seven cycles.", "study_duration": "Concurrent with radiotherapy (70 Gy/35 Fr).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:19.274613+00:00"}
{"study_id": 102503, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the efficacy, safety, and biomarkers of a triple combination therapy (FOLFOX, lenvatinib, and toripalimab) in advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis, not specifically focused on Alanine.", "results_summary": "The study found increased alanine aminotransferase levels as a common adverse event but did not assess Alanine's efficacy or safety as a supplement.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:21.892043+00:00"}
{"study_id": 102500, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to confirm the superiority of aponermin (a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand) plus thalidomide and dexamethasone over placebo plus thalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM).", "results_summary": "The study found that aponermin significantly improved progression-free survival, overall survival, and overall response rate compared to placebo, though it caused transient and reversible hepatotoxicity in some patients. The incidence of serious adverse events was similar between the two groups.", "population_specificity": "Patients with relapsed or refractory multiple myeloma who had previously received at least two regimens.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:22.297055+00:00"}
{"study_id": 102504, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of deferiprone versus deferoxamine in reducing iron overload in pediatric patients with sickle cell disease or other anemias.", "results_summary": "Deferiprone was found to be comparable to deferoxamine in reducing liver iron concentration and serum ferritin levels, with no new safety concerns observed. Common adverse events included upper abdominal pain, vomiting, and increased ALT/AST, but all resolved, mostly without intervention.", "population_specificity": "Pediatric patients (17 years and younger) with sickle cell disease or other anemias.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:22.500118+00:00"}
{"study_id": 102505, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effects of caper fruit on glycemic control, lipid profile, liver enzymes, and body mass in patients with metabolic disorders.", "results_summary": "The study found that caper fruit supplementation significantly reduced ALT levels, increased HDL, and decreased weight, but effects on AST, triglycerides, LDL, total cholesterol, and fasting blood glucose were not statistically significant.", "population_specificity": "Adults with non-alcoholic fatty liver disease (NAFLD), Type-2-Diabetes (T2D), metabolic syndrome, and hyperlipidemia.", "effective_dosage": "Not specified", "study_duration": "2 to 12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:22.750111+00:00"}
{"study_id": 102501, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare relapse rates of hepatitis B virus (HBV) after short finite intervals (6 vs. 12 months) of nucleos(t)ide analogue therapy in patients stratified by low or high HBV-DNA levels, focusing on virological and clinical relapse.", "results_summary": "The study found no difference in virological or clinical relapse rates between 6-month and 12-month treatment durations. High pretreatment HBV DNA and end-of-treatment HBsAg levels were predictors of virological relapse.", "population_specificity": "Patients with hepatitis B receiving chemotherapy, stratified by HBV-DNA levels (<2000 IU/ml or \u22652000 IU/ml).", "effective_dosage": "Not specified (tenofovir or entecavir started 1 week before chemotherapy).", "study_duration": "6 or 12 months post-chemotherapy cessation.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:23.049497+00:00"}
{"study_id": 102506, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers sought to evaluate the effects of conjugated linoleic acid (CLA) supplementation on glycemic control, adipokines, cytokines, malondialdehyde (MDA), and liver function enzymes in patients at risk of cardiovascular disease.", "results_summary": "CLA supplementation increased fasting blood glucose (FBG) and aspartate aminotransferase (AST) but decreased leptin and interleukin-6 (IL-6). No significant effects were observed on hemoglobin A1c (HbA1c), HOMA-IR, CRP, TNF-\u03b1, or alanine aminotransferase (ALT).", "population_specificity": "Patients at risk of cardiovascular disease", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:25.607860+00:00"}
{"study_id": 102508, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the spectrum of adverse events associated with antibody-drug conjugates in anticancer treatment, including effects on alanine aminotransferase levels.", "results_summary": "The study found that antibody-drug conjugates were associated with a higher risk of increased alanine aminotransferase (OR = 2.51, 95% CI = 1.84 to 3.40), indicating potential liver-related adverse effects. No increase in high-grade adverse events was observed.", "population_specificity": "10,075 patients involved in randomized controlled trials evaluating antibody-drug conjugates for anticancer treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:27.360717+00:00"}
{"study_id": 102509, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare sex differences in treatment outcomes (virologic, biochemical, complete response, and HCC incidence) among hepatitis B patients receiving nucleos(t)ide analogs.", "results_summary": "Females had similar virologic response and HCC incidence rates but lower biochemical and complete response rates compared to males. Male sex was associated with a higher likelihood of clinical remission and biochemical response.", "population_specificity": "Treatment-na\u00efve adult hepatitis B patients (1250 female, 2138 male) from 22 sites across Argentina, Korea, Japan, Taiwan, and the United States.", "effective_dosage": "Not specified", "study_duration": "5-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:29.611931+00:00"}
{"study_id": 102510, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of aldafermin (an FGF19 analog) in patients with compensated NASH cirrhosis.", "results_summary": "Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis compared to placebo, with 23% of patients achieving fibrosis improvement \u2265 1 stage. Adverse events, including diarrhea, were more frequent in higher-dose groups, leading to some discontinuations.", "population_specificity": "Patients with compensated NASH cirrhosis (n = 160).", "effective_dosage": "0.3 mg (discontinued), 1 mg, and 3 mg administered for 48 weeks.", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:31.706185+00:00"}
{"study_id": 102511, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the effect of dapagliflozin on liver fat content (LFC) and pancreatic fat content (PFC) in patients with type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Dapagliflozin significantly reduced LFC and PFC compared to the control group and improved serum levels of ALT, TNF-\u03b1, and IL-6.", "population_specificity": "84 patients with T2D and NAFLD.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:33.118176+00:00"}
{"study_id": 102512, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence and metabolic characteristics of lean/non-obese nonalcoholic fatty liver disease (NAFLD) in China, including comparisons of alanine transaminase levels between lean/non-obese and overweight/obese NAFLD patients.", "results_summary": "The study found that lean/non-obese NAFLD patients had lower alanine transaminase levels (30.28 IU/L) compared to overweight/obese NAFLD patients (33.12 IU/L), indicating a generally better metabolic profile in the former group.", "population_specificity": "229,091 lean/non-obese Chinese adults, including 22,641 diagnosed with NAFLD.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:33.167554+00:00"}
{"study_id": 102514, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the effects of n-3 PUFAs (not Alanine) in parenteral nutrition on liver function, inflammation, immune markers, and clinical outcomes in patients undergoing liver surgery.", "results_summary": "The study found that n-3 PUFAs significantly improved liver function markers (e.g., reduced AST and ALT levels), lowered inflammation (e.g., reduced IL-6), decreased infection complications, and shortened hospital stays compared to controls. No significant differences were observed for total bilirubin, TNF-\u03b1, IL-2, immunoglobulins, or mortality.", "population_specificity": "Patients undergoing liver surgery receiving parenteral nutrition.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:33.892206+00:00"}
{"study_id": 102513, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with NAFLD or NASH, focusing on changes in serum alanine transaminase levels and other liver and metabolic parameters.", "results_summary": "Semaglutide significantly reduced serum alanine transaminase and aspartate transaminase levels, improved liver fat content and stiffness, and enhanced metabolic parameters, but increased the risk of gastrointestinal and gallbladder-related adverse events.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:34.229010+00:00"}
{"study_id": 102515, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to evaluate the efficacy and safety of combining nivolumab and abemaciclib with fulvestrant or letrozole in HR-positive HER2-negative metastatic breast cancer, not specifically focused on alanine.", "results_summary": "The study reported elevated alanine aminotransferase levels as a common adverse event, suggesting potential liver toxicity, but did not assess alanine's direct effects or benefits.", "population_specificity": "Patients with HR-positive HER2-negative metastatic breast cancer (n=17).", "effective_dosage": "Not applicable (alanine was not a studied intervention).", "study_duration": "From June 2019 to July 2020 (early termination).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:35.819034+00:00"}
{"study_id": 102516, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers investigated the efficacy and safety of nivolumab maintenance therapy following platinum-based chemotherapy in EGFR-mutant NSCLC patients after EGFR-TKI failure, with a focus on outcomes like progression-free survival and adverse events.", "results_summary": "The study found that nivolumab maintenance therapy did not show clinical benefits, with a median PFS of 1.7 months and a 15.4% incidence of grade 3-4 treatment-related adverse events, including increased alanine aminotransferase in 7.7% of patients.", "population_specificity": "Patients aged 18+ with EGFR-mutant NSCLC that progressed after first- or second-line EGFR-TKI therapy.", "effective_dosage": "240 mg nivolumab every 2 weeks for 3 months, then 480 mg every 4 weeks.", "study_duration": "Until disease progression or unacceptable toxic effects occurred.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:38.984030+00:00"}
{"study_id": 102517, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to characterize the relationship between pegozafermin dosing, exposure, and effects on hepatic fat fraction (HFF) reduction in patients with NASH.", "results_summary": "Pegozafermin significantly reduced HFF, with the 30 mg weekly and 44 mg biweekly doses showing strong efficacy. The reduction in HFF was correlated with pegozafermin exposure, and baseline factors like body weight and alanine aminotransferase levels influenced outcomes.", "population_specificity": "Patients with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "30 mg weekly (q.w.) and 44 mg every 2 weeks (q2w).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:40.177044+00:00"}
{"study_id": 102520, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of vitamin E supplementation on serum alanine aminotransferase (ALT) levels in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Vitamin E supplementation at 400 IU/day and above significantly reduced ALT levels compared to placebo or no intervention, with greater reductions observed in non-Asian countries. AST levels also decreased, though the effect was smaller and less precise in non-Asian studies.", "population_specificity": "Patients with NAFLD, including both Asian and non-Asian populations.", "effective_dosage": "400 IU/day and above.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:43.541268+00:00"}
{"study_id": 102519, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the sensitivity and specificity of alanine-based amino acid ratio combinations as biomarkers for early identification of pyruvate dehydrogenase complex deficiency (PDCD).", "results_summary": "The study found that specific alanine-based amino acid ratio combinations (Ala/Lys \u22653.0 and Ala/Leu \u22655.0) effectively discriminated PDCD from other metabolic disorders with 100% sensitivity and ~85% specificity. These ratios were more sensitive than alanine alone or combinations with proline.", "population_specificity": "Patients with molecularly or enzymatically confirmed PDCD, other inborn errors of metabolism, and non-IEM conditions (201 subjects with a broad age range).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:44.229820+00:00"}
{"study_id": 102521, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to validate a severity grading system for post-KPE cholangitis and compare the efficacy of different antibiotic treatments, including their effects on alanine aminotransferase levels.", "results_summary": "In severe cholangitis, MEPM+IVIG reduced alanine aminotransferase levels and improved liver function compared to MEPM alone, but no significant differences were observed in recurrence rate, jaundice clearance, or native liver survival.", "population_specificity": "Patients with post-Kasai portoenterostomy cholangitis.", "effective_dosage": "Not specified for alanine aminotransferase-related outcomes.", "study_duration": "Follow-up at 1, 3, and 6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:44.515848+00:00"}
{"study_id": 102524, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the effects of cholecalciferol supplementation on NAFLD patients, including its impact on serum inflammatory biomarkers like alanine aminotransferase (ALT).", "results_summary": "Group 2 (cholecalciferol) showed significant reductions in ALT, lipid profile measures, and inflammatory markers compared to baseline and placebo, but no significant changes in glycemic index or AST.", "population_specificity": "100 patients with NAFLD and type 2 diabetes mellitus.", "effective_dosage": "Not specified for alanine (study focused on cholecalciferol).", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:45.257810+00:00"}
{"study_id": 102522, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy and safety of cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4) in patients with previously treated metastatic NSCLC, including those with primary or acquired resistance to immunotherapy.", "results_summary": "Cadonilimab showed limited efficacy, with an ORR of 10% in immunotherapy-na\u00efve patients and no responders in resistant cohorts. Safety was favorable, with only 11.3% of patients experiencing grade 3-4 adverse events, including a 1.9% incidence of increased alanine aminotransferase.", "population_specificity": "Patients with previously treated metastatic NSCLC, stratified into immunotherapy-na\u00efve (Cohort A), primary resistance (Cohort B), and acquired resistance (Cohort C) groups.", "effective_dosage": "6 mg/kg intravenously every 2 weeks.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:46.536234+00:00"}
{"study_id": 102518, "supplement_id": 863, "safety_score": "30", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucagon/GLP-1 receptor co-agonist NN1177, including its effects on weight loss and metabolic markers, in adults with overweight or obesity.", "results_summary": "NN1177 achieved clinically relevant weight loss (up to 12.6% at week 12) but was associated with several adverse effects, including increased heart rate, decreased reticulocyte count, elevated inflammation markers, and altered liver enzymes (aspartate and alanine aminotransferase). These safety signals halted further clinical development.", "population_specificity": "Adults with overweight or obesity (N = 99 in the MAD trial, N = 49 in the FHD/SAD trial, N = 45 in the drug-drug interaction trial).", "effective_dosage": "Escalating doses of 200, 600, 1300, 1900, 2800, 4200, and 6000 \u03bcg (MAD trial); single doses of 10, 40, 120, 350, 700, and 1100 \u03bcg (FHD/SAD trial); 4200 \u03bcg (drug-drug interaction trial).", "study_duration": "12 weeks (MAD trial); single-dose administration (FHD/SAD trial).", "interactions": "Tested with a Cooperstown 5 + 1 index cocktail in the drug-drug interaction trial.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:47.995038+00:00"}
{"study_id": 102525, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of TACE plus lenvatinib in treating advanced hepatocellular carcinoma (HCC), not specifically Alanine.", "results_summary": "The study found that TACE plus lenvatinib improved objective response rates, disease control rates, and survival outcomes compared to TACE or lenvatinib alone, but increased adverse events like hypertension and elevated liver enzymes.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:48.356845+00:00"}
{"study_id": 102526, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the impact of DAA therapy on metabolic changes, renal function, and anemia risk in patients with HCV infection, including effects on alanine aminotransferase levels.", "results_summary": "DAA therapy significantly reduced alanine aminotransferase levels, indicating improved liver function, but also led to decreased hemoglobin and hematocrit levels, increasing anemia incidence.", "population_specificity": "280 patients with HCV infection who achieved sustained virologic response after DAA therapy without ribavirin.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:49.082556+00:00"}
{"study_id": 102528, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of metformin in pediatric patients with non-alcoholic fatty liver disease (NAFLD), specifically focusing on its impact on alanine aminotransferase (ALT) levels.", "results_summary": "The meta-analysis found that metformin did not achieve a statistically significant improvement in ALT levels in pediatric NAFLD patients, with a weighted mean difference of -1.55 IU/L (95% CI: -5.38 to 2.28). The study included 4 randomized controlled trials but did not demonstrate meaningful clinical benefits for ALT reduction.", "population_specificity": "Pediatric patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:55.232747+00:00"}
{"study_id": 102530, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the hepatoprotective effects of propofol versus sevoflurane anesthesia on post-hepatectomy liver damage, as measured by AST and ALT levels.", "results_summary": "Propofol anesthesia resulted in significantly lower postoperative AST and ALT levels compared to sevoflurane, indicating a greater hepatoprotective effect during hepatectomy with the Pringle maneuver.", "population_specificity": "56 patients undergoing elective hepatectomies with the Pringle maneuver due to metastatic hepatic masses.", "effective_dosage": "Not specified", "study_duration": "Duration of anesthesia during surgery (not explicitly stated)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:55.452425+00:00"}
{"study_id": 102527, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The study aimed to compare the clinical effectiveness of dulaglutide and semaglutide in Japanese patients with type 2 diabetes, focusing on glycemic control and metabolic parameters.", "results_summary": "Semaglutide showed superior efficacy in reducing HbA1c, body mass index, visceral fat area, and liver fat percentage compared to dulaglutide, but had higher rates of gastrointestinal symptoms. Dulaglutide had fewer gastrointestinal side effects and better quality-of-life scores related to pain and gastrointestinal symptoms.", "population_specificity": "Japanese patients with type 2 diabetes (HbA1c \u22657%).", "effective_dosage": "Not specified (doses approved for use in Japan).", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:56.221283+00:00"}
{"study_id": 102529, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of combining Clearing Heat and Resolving Toxin (CHRT-CHF) traditional Chinese medicine with Transcatheter Arterial Chemoembolization (TACE) in treating primary liver cancer (PLC).", "results_summary": "The combined therapy (TACE plus CHRT-CHF) significantly improved 1- and 2-year survival rates, objective response rate (ORR), and disease control rate (DCR) compared to TACE alone. It also reduced liver function markers (AST, ALT), alpha-fetoprotein (AFP), and postembolization syndrome (PES).", "population_specificity": "Patients with unresected primary liver cancer (PLC).", "effective_dosage": "Optimal proportion of CHRT-CHF was 20-30% for efficacy and \u226540% for reducing PES (specific dosage not detailed).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:56.532262+00:00"}
{"study_id": 102531, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to update the epidemiology, clinical, and economic outcomes of patients diagnosed with chronic hepatitis B (CHB) infection in Taiwan, including the role of alanine aminotransferase laboratory tests in diagnosis.", "results_summary": "The study found that the prevalence of diagnosed CHB increased over the study period, with higher rates in older age groups and men. Complications such as cirrhosis and hepatocellular carcinoma were observed, and healthcare costs were higher with increasing disease severity.", "population_specificity": "Patients diagnosed with chronic hepatitis B (CHB) in Taiwan between 2010 and 2019.", "effective_dosage": "Not specified", "study_duration": "Median follow-up period of 6.42 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:57.905997+00:00"}
{"study_id": 102532, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the toxicity profiles of different ALK-TKIs, including their effects on alanine aminotransferase (ALT) levels, to guide clinical decision-making in treating advanced non-small cell lung cancer.", "results_summary": "The study found that elevated ALT or AST levels were among the most frequent adverse effects associated with crizotinib and brigatinib, but the toxicity spectra varied across ALK-TKIs. Alectinib showed the lowest rate of grade 3-4 adverse events (16.2%), while lorlatinib had the highest (91.6%).", "population_specificity": "Patients with advanced non-small cell lung cancer (3,353 participants across 13 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:59.139378+00:00"}
{"study_id": 102533, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a single intravenous infusion of an adeno-associated virus serotype 8 vector encoding UGT1A1 (GNT0003) in patients with Crigler-Najjar syndrome.", "results_summary": "The study found no serious adverse events, with common side effects being headache and elevated liver enzymes. Patients receiving the higher dose of GNT0003 showed reduced bilirubin levels and were able to discontinue phototherapy by the end of follow-up.", "population_specificity": "Patients with Crigler-Najjar syndrome undergoing phototherapy.", "effective_dosage": "Two patients received 2\u00d710^12 vector genomes/kg, and three received 5\u00d710^12 vector genomes/kg as a single infusion.", "study_duration": "Follow-up lasted up to 80 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:59.657147+00:00"}
{"study_id": 102534, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify predictive factors for pediatric choledocholithiasis using clinical data, including alanine transaminase levels, via a machine learning algorithm.", "results_summary": "The study found that elevated serum alanine transaminase levels were associated with choledocholithiasis in pediatric patients, and this factor was included in a highly predictive 9-feature machine learning model (AUC 0.935).", "population_specificity": "Children under 18 years of age who underwent cholecystectomy at 10 pediatric institutions.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:00.288526+00:00"}
{"study_id": 102536, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers sought to determine the effect of bariatric surgery on liver function, particularly focusing on alanine aminotransferase (ALT) levels, in people with obesity.", "results_summary": "Bariatric surgery significantly reduced ALT and GGT levels in patients with elevated baseline ALT, with sustained improvements over 60 months. The surgery also improved metabolic outcomes like HbA1c, blood pressure, and cholesterol levels.", "population_specificity": "511 patients with obesity who underwent bariatric surgery (71 sleeve gastrectomy, 440 gastric bypass).", "effective_dosage": "Not specified", "study_duration": "60 months of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:04.994252+00:00"}
{"study_id": 102537, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared demographic, laboratory data, and outcomes of COVID-19 patients infected with different SARS-CoV-2 variants (Alpha, Delta, Omicron), including levels of alanine transaminase (ALT).", "results_summary": "During the Omicron wave, hospitalized patients had lower median ALT levels compared to other variants, suggesting less liver involvement. The study did not focus on alanine as a supplement but rather as a biomarker.", "population_specificity": "Hospitalized COVID-19 patients in Iran during waves 4-6 (Alpha, Delta, Omicron variants).", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:06.767768+00:00"}
{"study_id": 102538, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the justification of eligibility criteria in acute leukemia trials, including AST/ALT (alanine aminotransferase) levels, and their concordance with drug safety data.", "results_summary": "The study found limited drug safety justifications for acute leukemia eligibility criteria, with AST/ALT criteria being concordant with safety data in 58.8% of trials, but criteria limits were more restrictive than safety-based limits in 51.4% of trials.", "population_specificity": "Patients eligible for front-line phase II and/or III acute leukemia trials registered on clinicaltrials.gov between 2010-2019.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:07.198416+00:00"}
{"study_id": 102535, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of brigatinib versus alectinib in patients with ALK+ NSCLC who had progressed on crizotinib, focusing on progression-free survival.", "results_summary": "The study found no significant difference in progression-free survival between brigatinib and alectinib, with median PFS of 19.3 and 19.2 months, respectively. Elevated levels of alanine aminotransferase (40% for brigatinib, 36% for alectinib) were among the common treatment-related adverse events.", "population_specificity": "Patients with advanced ALK+ NSCLC who had disease progression on crizotinib.", "effective_dosage": "Brigatinib 180 mg once daily (with a 7-day lead-in at 90 mg) or alectinib 600 mg twice daily.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:07.298149+00:00"}
{"study_id": 102540, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of gut microbiome-targeted therapies (probiotics, prebiotics, synbiotics) on liver enzymes, including alanine aminotransferase (ALT), in patients with NAFLD.", "results_summary": "The study found that microbiome-targeted therapies significantly reduced ALT levels in NAFLD patients, with probiotics and synbiotics showing the most pronounced effects, while prebiotics had no significant impact.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:07.616307+00:00"}
{"study_id": 102542, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 65, "study_goal": "The researchers aimed to compare the efficacy of a locally-produced HTK solution (containing Alanine) with the commercially available Custodiol HTK solution in adult liver transplantation candidates.", "results_summary": "The study found no statistically significant difference between the locally-produced HTK solution and Custodiol HTK in terms of efficacy, suggesting comparable performance in liver transplantation.", "population_specificity": "Adult patients undergoing liver transplantation.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:07.813031+00:00"}
{"study_id": 102541, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy of ginger supplementation versus placebo in reducing alanine aminotransferase (ALT) and other markers in patients with non-alcoholic fatty liver disease.", "results_summary": "Ginger supplementation significantly reduced ALT and HOMA-IR but showed no significant impact on AST, total cholesterol, LDL, or BMI.", "population_specificity": "Patients with non-alcoholic fatty liver disease (177 participants across four RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:07.881143+00:00"}
{"study_id": 102543, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the prognostic role of the elevated AST/ALT ratio (which includes alanine aminotransferase) in predicting major adverse cardio-cerebral events (MACCE) in patients with unstable angina undergoing percutaneous coronary intervention.", "results_summary": "The study found that a higher AST/ALT ratio was associated with increased risk of MACCE, particularly target vessel revascularization, with an optimal cutoff point of 1.29 for predicting adverse outcomes. The ratio remained significant in multivariate analysis, indicating its independent prognostic value.", "population_specificity": "1123 patients with unstable angina (mean age 62.3 years; 54.5% male) undergoing percutaneous coronary intervention.", "effective_dosage": "Not specified", "study_duration": "13 months of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:11.346075+00:00"}
{"study_id": 102551, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the efficacy and safety of camrelizumab plus rivoceranib versus sorafenib for unresectable hepatocellular carcinoma.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with unresectable or metastatic hepatocellular carcinoma.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:15.971171+00:00"}
{"study_id": 102549, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the effects of vitamin E supplementation on alanine aminotransferase (ALT) and other liver health markers in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Vitamin E supplementation significantly reduced ALT, AST, fibrosis, and steatosis in NAFLD patients but had no effect on GGT. Higher dosages (>600 IU/day) and longer treatment durations (\u226512 months) notably improved fibrosis scores.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": ">600 IU/day for fibrosis improvement.", "study_duration": "\u226512 months for fibrosis improvement.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:17.228248+00:00"}
{"study_id": 102545, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to examine the effect of hepatic steatosis (HS) on Asian patients with chronic hepatitis B (CHB), including its impact on antiviral therapy response and disease prognosis.", "results_summary": "The study found that HS prevalence in Asian CHB patients was 36.5%, negatively affecting antiviral therapy response (e.g., reduced HBeAg seroconversion and ALT normalization) and potentially exacerbating hepatocellular carcinoma (HCC) progression. No significant association was observed between HS and fibrosis or cirrhosis in CHB patients.", "population_specificity": "Asian patients with chronic hepatitis B (CHB) and hepatic steatosis (HS).", "effective_dosage": "Not specified", "study_duration": "48 weeks of treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:17.295479+00:00"}
{"study_id": 102544, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the anti-HBV efficacy, safety, and perinatal transmission outcomes of various ART regimens in pregnant women with HIV and HBV co-infection, including monitoring alanine aminotransferase (ALT) levels as a safety measure.", "results_summary": "The study found that HBV DNA suppression was similar with one or two HBV-active agents, HBeAg loss occurred in 44.4% of HBeAg-positive participants, and perinatal HBV transmission was low. Safety assessments showed few grade 3 or 4 ALT or AST elevations across treatment groups.", "population_specificity": "Pregnant women with HIV and HBV co-infection at 14 or more weeks of gestation.", "effective_dosage": "Not specified for Alanine (study focused on ART regimens).", "study_duration": "Antepartum period, with primary outcome measured at 8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:17.451008+00:00"}
{"study_id": 102548, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the prevalence of delirium and its risk factors, including the role of higher aspartic transaminase/alanine transaminase ratio, in hospitalized COVID-19 patients.", "results_summary": "The study found that a higher aspartic transaminase/alanine transaminase ratio was associated with an increased risk of delirium in COVID-19 patients (OR = 1.11, [95%CI 1.02-1.21], p = 0.018). However, the abstract does not provide specific results on the effects of alanine itself.", "population_specificity": "Hospitalized COVID-19 patients at seven tertiary hospitals.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:17.769852+00:00"}
{"study_id": 102552, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not assess Alanine; it focused on the efficacy and safety of parsaclisib in combination with obinutuzumab and bendamustine for relapsed or refractory follicular lymphoma.", "results_summary": "The study did not evaluate Alanine; it reported on the safety and efficacy of parsaclisib combination therapy, including adverse events like alanine aminotransferase increase in one patient.", "population_specificity": "Patients \u226518 years with relapsed or refractory CD20-positive follicular lymphoma.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:18.426354+00:00"}
{"study_id": 102550, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to determine the predictors of sustained stabilization of beta-cell function in early type 2 diabetes patients following short-term insulin therapy and metformin maintenance, with a focus on changes in hepatic insulin resistance and alanine aminotransferase.", "results_summary": "The study found that sustained stabilization of beta-cell function was associated with initial reversibility of beta-cell dysfunction during insulin induction and preservation of hepatic insulin sensitivity during metformin maintenance. Changes in alanine aminotransferase during maintenance were identified as an independent predictor of sustained stabilization.", "population_specificity": "Adults with \u22645-years duration of type 2 diabetes.", "effective_dosage": "Not specified for alanine.", "study_duration": "2 years (including 3-week induction and intermittent 2-week insulin courses every 3 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:20.819811+00:00"}
{"study_id": 102553, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of the Alanine, aspartate, and glutamate metabolism pathway in improving cognitive function in methamphetamine-dependent individuals through aerobic exercise training.", "results_summary": "The study found that aerobic exercise training significantly increased the Alanine, aspartate, and glutamate metabolism pathway in MA-dependent individuals, correlating with improved cognitive function. The modulation of gut microbiota and associated metabolic pathways, including Alanine metabolism, played a role in these cognitive improvements.", "population_specificity": "Methamphetamine-dependent individuals (n=64, split into aerobic exercise and conventional rehabilitation groups).", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:21.000831+00:00"}
{"study_id": 102554, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the effect of tofogliflozin on hepatic outcomes, including alanine transaminase (ALT) levels, in type 2 diabetes mellitus (T2DM) patients.", "results_summary": "The study found a significant decrease in ALT levels in the tofogliflozin group compared to control groups, along with improvements in other hepatic parameters like AST, GGT, ALP, and MRI-PDFF. No significant change was observed in adiponectin levels.", "population_specificity": "T2DM patients with concurrent liver disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:25.649535+00:00"}
{"study_id": 102557, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine if fasting plasma liver-expressed antimicrobial peptide 2 (FP-LEAP2) is linked to cardiometabolic disease markers in individuals with prediabetes and overweight/obesity, and whether antidiabetic interventions affect FP-LEAP2 levels.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "115 individuals with prediabetes (HbA1c 5.7%-6.4%) and overweight/obesity (BMI \u2265 25 kg/m\u00b2).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:26.868045+00:00"}
{"study_id": 102561, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of zinc supplementation on cardiovascular disease risk factors, including Alanine aminotransferase (ALT).", "results_summary": "The study found no noticeable effects of zinc supplementation on Alanine aminotransferase (ALT) levels. Zinc supplementation significantly improved other cardiovascular risk factors but did not impact ALT.", "population_specificity": "Not specified (meta-analysis of 75 randomized clinical trials).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:27.365381+00:00"}
{"study_id": 102560, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if the aspartate aminotransferase-to-alanine aminotransferase ratio (De Ritis ratio) could predict survival outcomes in stage II/III colorectal cancer patients.", "results_summary": "The De Ritis ratio was identified as an independent predictor for overall survival (OS) and disease-free survival (DFS) in stage II/III CRC patients. Nomograms incorporating this ratio and clinicopathological features showed improved accuracy and clinical utility compared to traditional staging systems.", "population_specificity": "4014 stage II/III primary colorectal cancer patients diagnosed between 2007 and 2013.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:27.830848+00:00"}
{"study_id": 102558, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the activity and safety of pembrolizumab in rare and ultra-rare sarcomas, not specifically Alanine.", "results_summary": "The study reported a 6.2% objective response rate with pembrolizumab in rare sarcomas, with manageable toxicity, including some cases of elevated alanine aminotransferase. However, the focus was not on Alanine as a supplement or therapeutic agent.", "population_specificity": "Patients with rare and ultra-rare sarcomas (incidence <1 per 1,000,000 people per year), aged 15+, with advanced disease.", "effective_dosage": "Pembrolizumab 200 mg intravenously every 21 days.", "study_duration": "Up to 24 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:29.170947+00:00"}
{"study_id": 102563, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the efficacy and safety of statins in reducing liver biochemical indicators, including alanine aminotransferase levels, in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that statins significantly reduced alanine aminotransferase levels in NAFLD patients, along with improvements in other liver enzymes and lipid profiles. The treatment group showed a 17% higher total effective rate compared to the control group.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:31.063957+00:00"}
{"study_id": 102556, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379) in combination with nucleos(t)ide analogues for treating chronic hepatitis B, including their impact on alanine aminotransferase levels and other HBV markers.", "results_summary": "The study found that JNJ-3989 led to a dose-dependent response in meeting nucleos(t)ide analogue-stopping criteria, with higher doses showing better efficacy. However, HBsAg seroclearance was rare, though most patients had clinically meaningful reductions in HBsAg. Safety profiles were generally favorable, with few serious adverse events related to treatment.", "population_specificity": "Patients aged 18-65 years with chronic hepatitis B (HBsAg positive, including virologically suppressed, HBeAg positive, and HBeAg negative individuals) across 19 countries.", "effective_dosage": "JNJ-3989 doses of 40 mg, 100 mg, or 200 mg every 4 weeks; JNJ-6379 250 mg daily.", "study_duration": "48 weeks of treatment followed by a follow-up phase.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:31.739184+00:00"}
{"study_id": 102562, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of bepirovirsen in reducing HBsAg and HBV DNA levels in participants with chronic HBV infection, both with and without background nucleos(t)ide analogue therapy.", "results_summary": "The study demonstrated that bepirovirsen induced rapid and prolonged HBsAg reduction with a favorable safety profile. The primary endpoint was HBsAg and HBV DNA seroclearance post-treatment, assessed in 457 participants.", "population_specificity": "Participants with chronic HBV infection, either receiving stable nucleos(t)ide analogue therapy (On-NA) or not currently on NA therapy (Not-on-NA).", "effective_dosage": "300 mg weekly (with or without loading doses of 300 mg on days 4 and 11), and 150 mg weekly in one arm.", "study_duration": "24 weeks (with variations in dosing regimens across arms).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:32.935546+00:00"}
{"study_id": 102566, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not evaluate Alanine's safety, efficacy, or quality; it focused on pembrolizumab and cabozantinib for metastatic renal cell carcinoma.", "results_summary": "The study did not report any findings related to Alanine.", "population_specificity": "Patients with metastatic renal cell carcinoma (clear-cell or non-clear cell histology).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:35.815302+00:00"}
{"study_id": 102564, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of seladelpar, a PPAR-\u03b4 agonist, in patients with primary biliary cholangitis who had an inadequate response or intolerance to UDCA.", "results_summary": "Seladelpar significantly improved liver biochemistry and reduced pruritus, with the 10 mg dose showing the most pronounced effects. Alanine aminotransferase levels decreased significantly with seladelpar compared to placebo, and no serious treatment-related adverse events were reported.", "population_specificity": "Patients with primary biliary cholangitis (PBC) who had inadequate response or intolerance to ursodeoxycholic acid (UDCA).", "effective_dosage": "5 mg and 10 mg daily", "study_duration": "12 months (study was terminated early, but primary and secondary endpoints were amended to month 3)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:37.380553+00:00"}
{"study_id": 102565, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy and safety of 4 mg saroglitazar treatment in patients with NAFLD or NASH, focusing on changes in serum alanine transaminase (ALT) levels and other liver and metabolic parameters.", "results_summary": "The study found that adjunct saroglitazar treatment significantly reduced ALT levels, improved liver stiffness, and enhanced metabolic parameters (serum glucose and lipid profile) in patients with NAFLD or NASH. The results were statistically significant with a mean difference of 26.01 U/L in ALT reduction.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).", "effective_dosage": "4 mg saroglitazar (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:38.334037+00:00"}
{"study_id": 102567, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to establish consensus on treatment endpoints for chronic HBV and HDV, including the role of alanine aminotransferase levels as an alternate endpoint in clinical trials.", "results_summary": "The study defined \"partial cure\" for chronic hepatitis B and alternate endpoints for chronic hepatitis D, including normalization of alanine aminotransferase levels combined with HDV RNA reduction. Alanine aminotransferase was noted as a biomarker but not its direct effects.", "population_specificity": "Patients with chronic hepatitis B (HBeAg positive or negative, treatment-naive or virally suppressed) and chronic hepatitis D (treatment-naive or experienced with quantifiable HDV RNA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:38.550062+00:00"}
{"study_id": 102568, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to describe the clinical and genetic features of a rare adolescent-onset CPS1D case with elevated blood alanine levels.", "results_summary": "The study found elevated blood alanine (757.06 \u00b5mol/L) in a patient with CPS1D, alongside other metabolic abnormalities, but did not assess alanine's therapeutic or adverse effects.", "population_specificity": "A single adolescent patient with childhood-onset CPS1D.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:38.589067+00:00"}
{"study_id": 102570, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the association between PCOS phenotypes and insulin resistance, including correlations with alanine transaminase levels.", "results_summary": "The study found a positive correlation between HOMA-IR (insulin resistance) and alanine transaminase levels in normal-weight PCOS women, suggesting a potential metabolic link. No direct effects or outcomes of alanine supplementation were assessed.", "population_specificity": "Women aged 18-40 years diagnosed with PCOS, categorized by BMI (normal weight and overweight/obese).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:41.101223+00:00"}
{"study_id": 102569, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and pharmacokinetics of ecnoglutide, a novel GLP-1 analog with an alanine substitution, in healthy participants.", "results_summary": "Ecnoglutide demonstrated potent in vitro activity and significant in vivo efficacy in reducing blood glucose and body weight in animal models, with favorable pharmacokinetics and tolerability in human trials.", "population_specificity": "Healthy participants (Phase 1 study) and animal models (db/db mice and DIO rats).", "effective_dosage": "SAD doses ranged from 0.03 to 1.0 mg; MAD doses ranged from 0.2 to 0.6 mg once weekly for 6 weeks.", "study_duration": "6 weeks (MAD phase).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:42.126130+00:00"}
{"study_id": 102571, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of bulevirtide in reducing HDV RNA and ALT levels in patients with chronic hepatitis D.", "results_summary": "Bulevirtide treatment at 2 mg and 10 mg doses significantly reduced HDV RNA levels and normalized ALT levels compared to the control group, with higher doses showing slightly better efficacy. The primary end-point response was achieved in 45% and 48% of patients in the 2-mg and 10-mg groups, respectively, versus 2% in the control group.", "population_specificity": "Patients with chronic hepatitis D, with or without compensated cirrhosis.", "effective_dosage": "2 mg per day or 10 mg per day, administered subcutaneously.", "study_duration": "144 weeks for treatment groups, 48 weeks for the control group followed by 96 weeks of treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:45.150830+00:00"}
{"study_id": 102573, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the causal relationship between NAFLD and changes in sleep traits, including associations with alanine transaminase levels.", "results_summary": "The study found significant associations between insomnia and elevated alanine transaminase levels (OR=2.79, P=4.71\u00d710-5) and between snoring and increased alanine transaminase levels (OR=1.27, P=0.04).", "population_specificity": "General population with genetic data from GWAS databases (specific demographics not detailed).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:46.344533+00:00"}
{"study_id": 102575, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated whether pre-infection metabolic dysregulation, including elevated alanine aminotransferase (ALT), was associated with severe COVID-19 outcomes in patients under 65 years of age.", "results_summary": "Elevated ALT (>40) was associated with a 1.74-fold increased risk of severe COVID-19 outcomes (hospitalization or death). The association was stronger in younger patients with metabolic risk factors.", "population_specificity": "Patients under 65 years of age with confirmed COVID-19 (n=3870).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:47.687033+00:00"}
{"study_id": 102574, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to investigate the effects of Chios Mastiha Essential Oil (CMEO) on metabolic abnormalities, including its impact on alanine aminotransferase levels in individuals with abdominal obesity and metabolic disorders.", "results_summary": "The study found that CMEO significantly decreased alanine aminotransferase levels (p = 0.022) and improved lipid profiles, blood pressure, and quality of life, with no reported adverse effects.", "population_specificity": "Individuals with abdominal obesity and metabolic abnormalities (e.g., dyslipidemia, hypertension, insulin resistance).", "effective_dosage": "200 mg of CMEO daily.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:47.834036+00:00"}
{"study_id": 102576, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize the effectiveness of peptides, including those containing alanine, in inhibiting DPP-IV and \u03b1-glucosidase for type 2 diabetes treatment.", "results_summary": "The study found that \u03b1-glucosidase inhibitory peptides containing alanine at the C-terminal are among the more active peptides, suggesting potential efficacy in diabetes management. The abstract highlights structural features of effective peptides but does not provide specific efficacy data for alanine alone.", "population_specificity": "Not specified (review of cellular and animal models).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:48.098125+00:00"}
{"study_id": 102572, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the effectiveness of daily and weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content (LFC), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels in patients with NAFLD and T2DM.", "results_summary": "The study found that daily GLP-1RAs, particularly semaglutide (qd), were more effective in improving AST and ALT levels compared to weekly treatments. Exenatide (bid) was the most effective for reducing LFC.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified for alanine aminotransferase (ALT) specifically; interventions included various GLP-1RAs (e.g., exenatide, liraglutide, dulaglutide, semaglutide).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:48.254106+00:00"}
{"study_id": 102578, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the impact of early gastroenterology/hepatology consultation on the management of severe immune checkpoint inhibitor-induced hepatitis, particularly focusing on alanine aminotransferase (ALT) normalization and improvement.", "results_summary": "Early consultation was not associated with faster ALT normalization in steroid-responsive hepatitis but was linked to faster ALT normalization and improvement in steroid-refractory cases, primarily due to earlier initiation of additional immunosuppressive therapy.", "population_specificity": "294 patients with grade \u22653 ICI-induced hepatitis (ALT >200 U/L).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:51.337007+00:00"}
{"study_id": 102577, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a prognostic model to predict 6-month mortality in patients with drug-induced liver injury (DILI), using alanine aminotransferase as one of the predictive parameters.", "results_summary": "The study developed a DILI mortality predictive (DMP) score incorporating alanine aminotransferase (ALT) as part of the formula, which accurately predicted 6-month mortality in DILI patients across multiple cohorts. The model demonstrated strong predictive performance, validated by AUC analysis.", "population_specificity": "DILI patients admitted to three hospitals (derivation cohort n=741, validation cohorts n=650 and n=617).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:51.390307+00:00"}
{"study_id": 102579, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize current knowledge on miRNA-based approaches, including miRNA-34a antagonist/inhibitor, for treating NAFLD/NASH.", "results_summary": "The study identified 56 miRNAs as potential therapeutic agents, with miRNA-34a antagonist/inhibitor being the most studied variant. The abstract does not mention specific results related to Alanine.", "population_specificity": "Not specified (focus on NAFLD/NASH patients, but no demographic details provided).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:54.200527+00:00"}
{"study_id": 102581, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of plant-based n-3 fatty acid supplementation on NAFLD surrogate biomarkers, including alanine aminotransferase (ALT).", "results_summary": "Plant-based n-3 supplementation significantly reduced ALT levels and plasma/serum triglycerides, alongside improvements in body-composition markers in NAFLD patients. The effects were statistically significant (P < 0.05).", "population_specificity": "Patients diagnosed with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:56.782920+00:00"}
{"study_id": 102580, "supplement_id": 863, "safety_score": "65", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of INCB053914, a pan-PIM kinase inhibitor, as monotherapy or in combination with standard-of-care agents for advanced hematologic malignancies, with a focus on adverse events including ALT/AST elevation.", "results_summary": "The study found that INCB053914 was generally well tolerated, with elevated ALT/AST being the most common adverse event. Limited therapeutic responses were observed in combination therapies, with two complete responses in AML patients and modest spleen volume reduction in MF patients.", "population_specificity": "Adults (\u226518 years) with advanced hematologic malignancies, including acute leukemia, MDS, MF, multiple myeloma, and lymphoproliferative neoplasms.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:58.127457+00:00"}
{"study_id": 102583, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the efficacy and safety of eribulin monotherapy versus eribulin plus anlotinib in patients with HER2-negative, locally recurrent or metastatic breast cancer, not specifically to evaluate Alanine.", "results_summary": "The study reported elevated alanine aminotransferase levels as a common adverse event in both treatment groups (62.5% in monotherapy vs. 75.0% in combination therapy), but did not assess Alanine's efficacy or safety as a supplement.", "population_specificity": "Patients with HER2-negative, locally recurrent or metastatic breast cancer previously treated with anthracycline- or taxane-based chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:58.376639+00:00"}
{"study_id": 102582, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the feasibility, safety, and efficacy of bulevirtide in patients with HBV/HDV-related cirrhosis and clinically significant portal hypertension, including those with HIV co-infection.", "results_summary": "Bulevirtide treatment led to a significant reduction in ALT levels (64.5% at month 6) and improvements in liver and spleen stiffness. HDV-RNA decline was similar in patients with and without HIV, and no adverse effects necessitated discontinuation.", "population_specificity": "Patients with HBV/HDV-related cirrhosis and clinically significant portal hypertension, including those with HIV co-infection (61.5% migrants).", "effective_dosage": "Not specified", "study_duration": "Median treatment duration was 11 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:59.383029+00:00"}
{"study_id": 102584, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and toxicity of ruxolitinib in treating steroid-refractory graft-versus-host disease (SR-GVHD) in children, not Alanine.", "results_summary": "The study found that ruxolitinib had an overall response rate of 64.3% in pediatric SR-GVHD patients, with adverse effects observed in 64.3% of cases, including elevated alanine aminotransferase. No results specific to Alanine were reported.", "population_specificity": "Pediatric patients (ages 3 months to 12 years) with SR-GVHD after allogeneic hematopoietic stem cell transplantation.", "effective_dosage": "Not applicable (study focused on ruxolitinib, not Alanine).", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned (study did not assess Alanine-specific interactions).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:59.455443+00:00"}
{"study_id": 102585, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers investigated the association of liver markers, including alanine aminotransferase (ALT), with heart failure outcomes and the treatment effect of empagliflozin in patients with HFpEF.", "results_summary": "High ALT was associated with better outcomes for heart failure hospitalization or cardiovascular death, while empagliflozin had no significant effect on ALT levels. The treatment benefits of empagliflozin were not influenced by baseline liver parameters.", "population_specificity": "5988 patients with heart failure with preserved ejection fraction (HFpEF), excluding those with significant liver disease.", "effective_dosage": "Not specified for alanine (study focused on empagliflozin 10 mg daily).", "study_duration": "Not specified for alanine (study duration not detailed in abstract).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:02.040795+00:00"}
{"study_id": 102586, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers evaluated the efficacy and safety of tazobactam/ceftolozane (TAZ/CTLZ) in combination with metronidazole for intraabdominal infections in the hepato-biliary-pancreatic field, not specifically Alanine.", "results_summary": "The study found a clinical cure rate of 91.8% at end-of-therapy and 89.6% at test-of-cure, with minor adverse events like increased alanine aminotransferase in 6% of patients. The efficacy decreased in compromised patients, such as those with recurrent cancer or post-surgical complications.", "population_specificity": "50 patients with intraabdominal infections (abscess, peritonitis, liver abscess, cholecystitis, cholangitis with sepsis).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:03.183638+00:00"}
{"study_id": 102587, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of vorasidenib, an inhibitor of mutant IDH enzymes, in patients with grade 2 IDH-mutant glioma, with a focus on progression-free survival and time to next intervention.", "results_summary": "Vorasidenib significantly improved progression-free survival (27.7 months vs. 11.1 months) and delayed the time to the next intervention compared to placebo. However, it was associated with a higher incidence of grade 3 or higher adverse events, including elevated alanine aminotransferase levels (9.6% vs. 0%).", "population_specificity": "Patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery.", "effective_dosage": "40 mg once daily in 28-day cycles.", "study_duration": "Median follow-up of 14.2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:05.811628+00:00"}
{"study_id": 102590, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of the Mediterranean diet on NAFLD patients, including markers like alanine aminotransferase (ALT).", "results_summary": "The study found that the Mediterranean diet may reduce liver stiffness, though the effect on ALT was not explicitly detailed in the abstract. The meta-analysis included 10 RCTs with mixed but generally positive outcomes.", "population_specificity": "737 adults with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified (dietary intervention).", "study_duration": "6 weeks to 1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:07.850245+00:00"}
{"study_id": 102589, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether whey protein supplementation (WPS) enhances the effects of resistance exercise on hepatic fat content (HFC) and lipid profiles.", "results_summary": "WPS did not significantly enhance the overall effects of resistance exercise on HFC and lipid profiles but may have partially beneficial effects on liver enzymatic changes and rapid response to HFC reduction.", "population_specificity": "Sedentary males", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:08.020963+00:00"}
{"study_id": 102592, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effect of SGLT-2 inhibitors on NAFLD patients' outcomes, including changes in liver enzymes such as alanine transaminase (ALT).", "results_summary": "The study found that SGLT-2 inhibitors had positive effects on liver enzymes (ALT, AST, GGT), lipid profiles, and BMI in NAFLD patients, with statistically significant improvements reported in multiple trials.", "population_specificity": "NAFLD patients, with or without type 2 diabetes (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:08.161184+00:00"}
{"study_id": 102588, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to study the pharmacokinetic drug-drug interactions of HP501, febuxostat, and colchicine in hyperuricemic patients, focusing on safety and efficacy.", "results_summary": "Coadministration of HP501, febuxostat, and colchicine did not produce clinically meaningful pharmacokinetic interactions. HP501 alone reduced serum uric acid (sUA) by 24.77%, while combined with febuxostat, it led to a 55.82% reduction, with all patients achieving sUA < 360 \u03bcmol/L. Adverse events were mild or moderate, primarily diarrhea and elevated ALT levels.", "population_specificity": "Hyperuricemic patients", "effective_dosage": "HP501 40 mg once daily; febuxostat 40 mg once daily; colchicine 0.5 mg once daily", "study_duration": "7-12 days", "interactions": "No significant pharmacokinetic interactions between HP501, febuxostat, and colchicine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:08.538697+00:00"}
{"study_id": 102593, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on immune checkpoint inhibitors (IN) for melanoma brain metastasis (MBM) patients.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Melanoma patients with brain metastases (MBM).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:09.216847+00:00"}
{"study_id": 102591, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether blood levels of alanine phosphatase (ALP) and gamma-glutamyl-transferase (GGT) could predict survival in metastatic pancreatic cancer patients.", "results_summary": "Patients with low GGT levels lived longer, while those with liver metastasis and high ALP/GGT levels had worse prognoses. Higher ALP and GGT levels were associated with poor prognosis in pancreatic cancer patients with liver metastasis receiving nab-paclitaxel/gemcitabine treatment.", "population_specificity": "153 patients with metastatic pancreatic cancer receiving first-line treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:09.464856+00:00"}
{"study_id": 102594, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the demographic and clinical characteristics of patients with Lysosomal Acid Lipase Deficiency (LAL-D), focusing on common manifestations such as elevated alanine aminotransferase levels.", "results_summary": "Elevated alanine aminotransferase levels were a common manifestation (70%) raising suspicion of LAL-D, but the study did not evaluate alanine's efficacy or safety as a supplement.", "population_specificity": "Patients diagnosed with LAL-D, including children (\u22656 months to <18 years) and adults.", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:12.539469+00:00"}
{"study_id": 102595, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the effectiveness of herbal medicines, including those affecting alanine aminotransferase (ALT), in treating cirrhosis.", "results_summary": "Three of six studies showed beneficial effects of silymarin on ALT levels in cirrhosis patients, but the abstract does not specifically isolate alanine's role.", "population_specificity": "Patients with cirrhosis (613 patients across eight studies for silymarin, 118 for curcumin, and 4 for ginseng).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:14.367317+00:00"}
{"study_id": 102596, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to systematically evaluate the effects of chicory (not Alanine) on liver function and lipid profile in patients with NAFLD.", "results_summary": "Chicory significantly reduced aspartate transaminase and alanine transaminase levels but had no significant effects on alkaline phosphatase, gamma-glutamyl transferase, or lipid profile components.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:16.092388+00:00"}
{"study_id": 102599, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the effect of turmeric/curcumin supplementation on liver function tests, including alanine aminotransferase (ALT).", "results_summary": "Turmeric/curcumin supplementation significantly reduced ALT levels (WMD = -4.09 U/L), though the clinical relevance remains uncertain. No significant effect was observed on GGT levels.", "population_specificity": "Participants in randomized controlled trials (RCTs) examining liver function.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:16.696851+00:00"}
{"study_id": 102601, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify potential mechanisms of SARS-CoV-2-induced liver damage, including the role of Alanine aminotransferase elevation, and explore treatment outcomes in infected patients.", "results_summary": "The study found that liver damage in COVID-19 patients is marked by elevated Alanine aminotransferase levels and histopathological changes, but it did not assess Alanine's direct effects or therapeutic use.", "population_specificity": "SARS-CoV-2-infected patients with liver damage.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:17.803530+00:00"}
{"study_id": 102598, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers examined the impact of ursodeoxycholic acid (UDCA) on liver enzymes, HbA1c, lipids, and inflammation markers after bariatric surgery, not specifically Alanine.", "results_summary": "UDCA led to a clinically insignificant increase in alkaline phosphatase (ALP) and lower alanine aminotransferase (ALT) levels post-surgery, but no other metabolic or inflammatory marker changes were observed.", "population_specificity": "Patients who underwent bariatric surgery (mean age 45.6 \u00b1 10.7 years, 79% female).", "effective_dosage": "900 mg daily", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:18.298999+00:00"}
{"study_id": 102600, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effects of postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) on alanine aminotransferase levels and other serum electrolytes in patients who underwent open radical gastrectomy.", "results_summary": "The study found statistical differences in alanine aminotransferase levels between the HIPEC and control groups, but the effects of HIPEC on alanine aminotransferase needed further exploration. No significant differences were found in hemoglobin, white blood cell count, platelet count, aspartate aminotransferase, total bilirubin, or uric acid between the groups.", "population_specificity": "153 patients who underwent open radical gastrectomy (83 in the HIPEC group, 70 in the control group).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:19.749220+00:00"}
{"study_id": 102602, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of tropifexor (TXR) and cenicriviroc (CVC) combination therapy, including its impact on alanine aminotransferase (ALT) levels, in patients with NASH.", "results_summary": "The study found that TXR monotherapy and combination therapies led to sustained decreases in ALT levels and body weight, but no substantial incremental efficacy was observed with the combination compared to monotherapy. Histological improvements were modest and similar across treatment groups.", "population_specificity": "Patients with NASH (N = 193).", "effective_dosage": "TXR 140 \u03bcg, TXR 90 \u03bcg, and CVC 150 mg, administered once daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:20.057692+00:00"}
{"study_id": 102603, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate whether prophylactic terlipressin reduces the occurrence of severe postreperfusion syndrome (PRS) in deceased donor liver transplantation, with secondary outcomes including effects on alanine transaminase levels.", "results_summary": "Prophylactic terlipressin significantly reduced the incidence of severe PRS and peak alanine transaminase levels post-transplantation, though it increased pulmonary capillary wedge pressure and prolonged mechanical ventilation time.", "population_specificity": "Adults undergoing deceased donor liver transplantation.", "effective_dosage": "1 mg of terlipressin immediately after portal vein clamping.", "study_duration": "Single dose administered perioperatively.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:22.161525+00:00"}
{"study_id": 102604, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not assess Alanine; it focused on tucatinib plus trastuzumab for HER2-positive metastatic colorectal cancer.", "results_summary": "The study did not evaluate Alanine; it reported outcomes related to tucatinib and trastuzumab therapy.", "population_specificity": "Patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:22.819634+00:00"}
{"study_id": 102605, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to investigate metabolic bone disease (hepatic osteodystrophy) and thyroid dysfunction in patients with chronic liver disease (CLD) and cirrhosis, not specifically Alanine.", "results_summary": "The study found vitamin D deficiency, raised PTH, and low urinary calcium in a CLD patient with osteomalacia, and thyroid dysfunction (lower FT3, FT4, higher TSH) correlated with liver cirrhosis severity.", "population_specificity": "Patients with chronic liver disease (CLD) and liver cirrhosis.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:25.896625+00:00"}
{"study_id": 102608, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the therapeutic effect of ulinastatin (UTI) on unliquefied pyogenic liver abscesses complicated by septic shock (UPLA-SS), including its impact on liver function and inflammatory markers.", "results_summary": "UTI combined with conventional treatment significantly reduced inflammatory markers, improved liver function, and shortened treatment time in patients with UPLA-SS compared to the control group, though mortality rates did not differ significantly.", "population_specificity": "Patients with unliquefied pyogenic liver abscesses complicated by septic shock (UPLA-SS).", "effective_dosage": "200,000 units q8h for >3 days.", "study_duration": ">3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:28.491700+00:00"}
{"study_id": 102606, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of MSB2311, a PD-L1 monoclonal antibody, in patients with advanced solid tumors or lymphoma.", "results_summary": "MSB2311 showed manageable safety with common adverse events like anemia and elevated liver enzymes, and demonstrated promising antitumor activity, with a 30% objective response rate in biomarker-positive solid tumors and one partial response in lymphoma patients.", "population_specificity": "37 Chinese patients (31 with solid tumors, 6 with lymphoma) with specific biomarker profiles.", "effective_dosage": "3, 10, and 20 mg/kg every 3 weeks (Q3W) and 10 mg/kg every 2 weeks (Q2W).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:29.010925+00:00"}
{"study_id": 102607, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the clinical efficacy of probiotics, including their effect on alanine aminotransferase (ALT) levels, in the treatment of patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The meta-analysis found that probiotic adjuvant therapy significantly reduced ALT levels (MD: -0.07; 95% CI: -12.95, -7.19) and improved other liver function markers, lipid metabolism, blood glucose, and inflammatory factors in NAFLD patients. The treatment effect was more pronounced when the intervention lasted over 12 weeks.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Treatment duration varied, with more pronounced effects observed when exceeding 12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:29.091614+00:00"}
{"study_id": 102610, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a predictive nomogram for HBV-related hepatocellular carcinoma (HCC) survival rates, incorporating alanine aminotransferase levels as one of the independent variables.", "results_summary": "The study found that alanine aminotransferase levels were an independent predictive variable for overall survival in HBV-related HCC patients. The nomogram, which included this factor, showed good performance in predicting 1-, 2-, and 3-year survival rates.", "population_specificity": "2281 HCC patients with HBV-related diagnosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:29.794168+00:00"}
{"study_id": 102609, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the pharmacokinetics of rivaroxaban in real-world patients and identify covariates affecting its variability, including alanine aminotransferase.", "results_summary": "The study found that alanine aminotransferase, among other covariates, influenced the clearance of rivaroxaban, contributing to significant interindividual variability in pharmacokinetics. The results may guide clinicians in adjusting therapeutic regimens.", "population_specificity": "20 real-world patients (50% men/50% women) with a mean age of 53.1 years and mean body weight of 81.7 kg.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:30.670947+00:00"}
{"study_id": 102611, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to determine the safety and efficacy of mTOR inhibitor nab-sirolimus combined with nivolumab in patients with advanced sarcoma or tumors with mTOR pathway mutations, not Alanine.", "results_summary": "The study found that nivolumab plus nab-sirolimus was safe with no unexpected adverse events but did not improve treatment outcomes; best responders had specific genetic mutations. The abstract does not mention Alanine.", "population_specificity": "Patients \u226518 years with advanced sarcoma or tumors with mTOR pathway mutations.", "effective_dosage": "Not mentioned (for Alanine).", "study_duration": "Not mentioned (for Alanine).", "interactions": "None mentioned (for Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:31.824453+00:00"}
{"study_id": 102612, "supplement_id": 863, "safety_score": "70", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pegbelfermin, a polyethylene glycol-conjugated analog of human fibroblast growth factor 21, in patients with nonalcoholic steatohepatitis (NASH) and compensated cirrhosis.", "results_summary": "Pegbelfermin did not significantly improve fibrosis scores compared to placebo, though it showed some improvements in liver stiffness, steatosis, and inflammation markers. Serious adverse events were more frequent with pegbelfermin, but none were treatment-related.", "population_specificity": "Adults with biopsy-confirmed NASH and stage 4 fibrosis (compensated cirrhosis).", "effective_dosage": "10, 20, or 40 mg injected subcutaneously once weekly.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:34.010374+00:00"}
{"study_id": 102613, "supplement_id": 863, "safety_score": "85", "efficacy_score": 60, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pegbelfermin, a fibroblast growth factor 21 analog, in patients with NASH and stage 3 fibrosis over 48 weeks.", "results_summary": "Pegbelfermin showed modest improvements in hepatic fat reduction and liver injury markers but did not meet the primary endpoint of fibrosis improvement without NASH worsening. Adverse events were similar across treatment and placebo groups, with no serious treatment-related events reported.", "population_specificity": "Patients with biopsy-confirmed NASH and stage 3 (bridging) fibrosis (N = 197).", "effective_dosage": "Weekly subcutaneous injections of 10, 20, or 40 mg pegbelfermin.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:37.349096+00:00"}
{"study_id": 102614, "supplement_id": 863, "safety_score": "65", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the clinical features of adverse drug events (ADEs) associated with eltrombopag, including effects on alanine aminotransferase levels, across different age groups.", "results_summary": "The study observed signals of elevated alanine aminotransferase levels in all age groups, indicating potential liver-related adverse effects. No direct efficacy outcomes for alanine were reported.", "population_specificity": "Patients of various age groups (0-17, 18-64, \u226565 years) using eltrombopag for immune thrombocytopenia, chronic hepatitis C-related thrombocytopenia, or aplastic anemia.", "effective_dosage": "Not specified", "study_duration": "Data collected from 2008 to 2022", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:38.546440+00:00"}
{"study_id": 102615, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to examine the impact of meal glycaemic load (GL) on postprandial plasma metabolome responses, including alanine levels, in overweight postmenopausal women with and without Metabolic Syndrome (MetS).", "results_summary": "The study found that postprandial alanine levels were higher following a low GL meal compared to a high GL meal in overweight women with MetS, though meal GL had minimal overall impact on the metabolome.", "population_specificity": "Overweight postmenopausal women (Healthy: n=20; MetS: n=20).", "effective_dosage": "Not specified (test meals contained 73 g carbohydrate, 51% energy).", "study_duration": "Acute intervention (single meal).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:39.397425+00:00"}
{"study_id": 102616, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the pharmacokinetics, safety, tolerability, and effects on aminotransferases (specifically ALT) of elafibranor in children with NASH.", "results_summary": "Elafibranor was well tolerated and rapidly absorbed, with a 37.4% relative reduction in mean ALT levels in the 120 mg group after 12 weeks, suggesting potential improvement in liver histology.", "population_specificity": "Children aged 8-17 years with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "80 mg or 120 mg daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:39.539136+00:00"}
{"study_id": 102617, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify potential biomarkers, including alanine metabolism, involved in the early molecular response to hypoxic-ischemic encephalopathy in newborns.", "results_summary": "The study found that alanine metabolism, along with aspartate and glutamate metabolism, was involved in the early molecular response to hypoxic-ischemic encephalopathy, suggesting a potential role in the condition's pathophysiology.", "population_specificity": "Newborns >36 weeks who suffered perinatal asphyxia and met diagnostic criteria for hypoxic-ischemic encephalopathy.", "effective_dosage": "Not specified", "study_duration": "Samples were collected within the first 72 hours post-insult.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:39.547200+00:00"}
{"study_id": 102619, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it compares the efficacy and safety of bepotastine besilate versus levocetirizine in chronic spontaneous urticaria.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with chronic spontaneous urticaria.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:39.697548+00:00"}
{"study_id": 102618, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for advanced non-small cell lung cancer after PD-(L)1 inhibitor failure, not specifically Alanine.", "results_summary": "The study found nab-paclitaxel improved the objective response rate (55.2%) and disease control rate (86.2%) with a median progression-free survival of 5.6 months and acceptable toxicities. Alanine aminotransferase elevation was noted as a grade 3 or higher toxicity in 3.4% of cases.", "population_specificity": "Patients with advanced non-small cell lung cancer who had failed PD-(L)1 inhibitor therapy.", "effective_dosage": "100 mg/m\u00b2 of nab-paclitaxel.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:41.765837+00:00"}
{"study_id": 102620, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the relationship between liver function and rhabdomyolysis (RM) in hemorrhagic trauma patients, focusing on the role of alanine transferase (ALT) as a biomarker.", "results_summary": "The study found a significant positive correlation between RM biomarkers (CK and myoglobin) and liver biomarkers (AST, ALT, and bilirubin), with intense RM associated with higher liver failure rates. Liver failure was more common in patients with intense RM and linked to renal replacement therapy and SOFA scores.", "population_specificity": "Severely injured trauma patients transfused within 24 hours and admitted to ICU, excluding those with significant direct liver injury.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:44.966079+00:00"}
{"study_id": 102621, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to study clinic-radiologic profiles, risk factors, complications, and outcomes of pediatric liver abscess, including predictors of poor outcomes such as elevated alanine transaminase.", "results_summary": "Elevated alanine transaminase was significantly associated with poor outcomes in pediatric liver abscess patients. The study did not focus on alanine as a supplement but as a biomarker.", "population_specificity": "Children under 12 years of age with ultrasonographically diagnosed liver abscess in a tertiary care hospital in India.", "effective_dosage": "Not applicable", "study_duration": "Retrospective study from January 2019 to September 2019.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:46.747321+00:00"}
{"study_id": 102623, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to report a successful diagnosis and treatment case of descending necrotizing mediastinitis (DNM) caused by Streptococcus constellatus, focusing on surgical and antibiotic interventions.", "results_summary": "The study found that timely surgical drainage and antibiotic therapy led to the resolution of the abscess and normalization of alanine transaminase levels, among other markers, with no recurrence at 3-month follow-up.", "population_specificity": "A 53-year-old male with DNM originating from oral to neck and mediastinum.", "effective_dosage": "Not specified", "study_duration": "4 weeks of antibiotic therapy", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:48.712656+00:00"}
{"study_id": 102624, "supplement_id": 863, "safety_score": "70", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of fitusiran prophylaxis, which targets antithrombin, in reducing bleeding rates in individuals with haemophilia A or B with inhibitors.", "results_summary": "Fitusiran prophylaxis significantly reduced the annualised bleeding rate by 90.8% compared to on-demand bypassing agents, with 66% of participants experiencing zero treated bleeds. The most frequent adverse event was increased alanine aminotransferase in 32% of participants, and two cases of thromboembolic events were reported.", "population_specificity": "Men, boys, and young adults aged 12 years or older with severe haemophilia A or B with inhibitors.", "effective_dosage": "80 mg subcutaneous once-a-month.", "study_duration": "9 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:49.908411+00:00"}
{"study_id": 102622, "supplement_id": 863, "safety_score": "65", "efficacy_score": 25, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of BPI-9016M, a c-MET inhibitor, in patients with locally advanced or metastatic NSCLC harboring c-MET overexpression or MET exon 14 skipping mutation.", "results_summary": "BPI-9016M showed a manageable safety profile but limited efficacy, with common treatment-related adverse events including elevated ALT (36.8%) and AST (28.9%). The objective response rate was low (2.6%), and disease control rate was modest (42.1%).", "population_specificity": "Patients with locally advanced or metastatic NSCLC and c-MET overexpression or MET exon 14 skipping mutation.", "effective_dosage": "300 mg QD, 450 mg QD, 600 mg QD (Part A); 400 mg BID (Part B).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:50.456127+00:00"}
{"study_id": 102625, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of fitusiran prophylaxis, which targets antithrombin, in reducing bleeding rates in people with severe haemophilia A or B without inhibitors.", "results_summary": "Fitusiran prophylaxis significantly reduced the annualised bleeding rate compared to on-demand clotting factor concentrates, with 51% of participants experiencing no treated bleeds. The most common adverse event in the fitusiran group was increased alanine aminotransferase concentration, but no treatment-related thrombosis or deaths were reported.", "population_specificity": "Male participants aged at least 12 years with severe haemophilia A or B without inhibitors.", "effective_dosage": "80 mg subcutaneous fitusiran once per month.", "study_duration": "9 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:51.080538+00:00"}
{"study_id": 102626, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to determine the safety and pharmacokinetic profile of the monoclonal antibody CAP256V2LS, alone and in combination with VRC07-523LS, in young HIV-negative women.", "results_summary": "The study found that CAP256V2LS, administered alone or in combination, was safe with no serious adverse events or dose-limiting toxicities. Commonly reported symptoms included headaches, chills, and fatigue, with transient lymphocytopenia and elevated liver enzymes noted in some participants.", "population_specificity": "Young HIV-negative women aged 18-45 in Durban, South Africa.", "effective_dosage": "5 mg/kg and 10 mg/kg intravenously; 5 mg/kg, 10 mg/kg, and 20 mg/kg subcutaneously.", "study_duration": "From July 13, 2020, to Jan 13, 2021 (approximately 6 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:52.381032+00:00"}
{"study_id": 102627, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and tolerability of eganelisib (IPI-549), a PI3K\u03b3 inhibitor, as monotherapy and in combination with nivolumab in patients with solid tumors, including its effects on hepatic enzymes like alanine aminotransferase (ALT).", "results_summary": "The study found that eganelisib monotherapy and combination therapy led to grade \u22653 hepatic enzyme elevations (ALT, AST) in some patients, with reversible toxicity. Antitumor activity was observed in combination therapy, including in patients previously resistant to PD-1/PD-L1 inhibitors.", "population_specificity": "Patients with solid tumors.", "effective_dosage": "Monotherapy: 10-60 mg once daily; Combination therapy: 20-40 mg once daily with nivolumab.", "study_duration": "Not specified in the abstract.", "interactions": "Combination with nivolumab (PD-1 inhibitor).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:53.407151+00:00"}
{"study_id": 102628, "supplement_id": 863, "safety_score": "70", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers evaluated the safety and clinical activity of bintrafusp alfa, a bifunctional fusion protein, in patients with locally advanced or metastatic biliary tract cancer.", "results_summary": "The study found that 10.7% of patients achieved an objective response, with a median duration of response of 10.0 months. Grade \u22653 adverse events occurred in 26.4% of patients, including increased alanine aminotransferase (1.9%).", "population_specificity": "Adults with locally advanced or metastatic biliary tract cancer who had failed first-line platinum-based chemotherapy.", "effective_dosage": "1200 mg intravenously every 2 weeks.", "study_duration": "Median follow-up was 16.1 months (range, 0.0-19.3 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:55.937436+00:00"}
{"study_id": 102629, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the real-world efficacy and safety of atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma (HCC), including the impact of alanine aminotransferase (ALT) levels on outcomes.", "results_summary": "Increased ALT levels were associated with significantly shorter overall survival (OS) and progression-free survival (PFS), with hazard ratios of 6.68 and 3.54, respectively. Proteinuria, however, was linked to longer OS.", "population_specificity": "268 patients with unresectable hepatocellular carcinoma (HCC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:56.896926+00:00"}
{"study_id": 102631, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify plasma biomarkers, including alanine transaminase, for early diagnosis of sepsis-associated liver dysfunction (SALD).", "results_summary": "The study analyzed alanine transaminase among other biomarkers but did not specifically highlight its predictive value for SALD or survival outcomes. PAI-1 was identified as a significant predictor.", "population_specificity": "79 patients with sepsis and septic shock treated in the ICU.", "effective_dosage": "Not specified", "study_duration": "Plasma samples were obtained within 24 hours of sepsis/septic shock onset; patients were followed for 14 days for SALD development and 28 days for survival.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:59.303192+00:00"}
{"study_id": 102630, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of Fuzheng Huayu preparation (FZHY) plus tenofovir disoproxil fumarate (TDF) on hepatitis B, focusing on liver function and fibrosis markers, including alanine transaminase levels.", "results_summary": "The combination therapy significantly reduced levels of alanine transaminase, aspartate aminotransferase, and fibrosis markers compared to TDF alone. Subgroup analyses indicated improved albumin levels in chronic hepatitis B patients and greater benefits with treatment durations exceeding 24 weeks.", "population_specificity": "Patients with hepatitis B, including those with chronic hepatitis B and hepatitis B-related cirrhosis.", "effective_dosage": "Not specified", "study_duration": "Varied, with subgroup analyses comparing \u2264 24-week and > 24-week durations.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:59.462541+00:00"}
{"study_id": 102633, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 70, "study_goal": "To evaluate the safety and efficacy of fixed-dose sofosbuvir/ledipasvir combination in kidney transplant recipients with hepatitis C virus infection.", "results_summary": "All patients achieved sustained virologic response (SVR12) with no graft failures or deaths reported. The treatment was effective and safe, though cautious monitoring of calcineurin inhibitor trough levels was advised due to potential drug-drug interactions.", "population_specificity": "Kidney transplant recipients with chronic hepatitis C virus infection.", "effective_dosage": "Fixed-dose sofosbuvir/ledipasvir combination for 12 or 24 weeks, with or without ribavirin (specific dosage not detailed).", "study_duration": "12 or 24 weeks.", "interactions": "Potential drug-drug interactions with calcineurin inhibitors.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:01.494233+00:00"}
{"study_id": 102635, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to analyze hematological and biochemical parameters, including alanine transaminase, in children with cerebral palsy to understand their health status.", "results_summary": "The study reported mean values for alanine transaminase but did not specifically evaluate its efficacy or safety. Abnormal alkaline phosphatase levels were more common in younger patients and females.", "population_specificity": "Children with cerebral palsy admitted to a pediatric department of a medical college teaching hospital.", "effective_dosage": "Not available", "study_duration": "Four-year observational study", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:02.286791+00:00"}
{"study_id": 102634, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and effectiveness of adjuvant UFT/LV chemotherapy in elderly patients (\u226580 years) with stage III colorectal cancer.", "results_summary": "The study found a 67.3% completion rate for UFT/LV therapy, with 21 patients discontinuing due to adverse events or refusal. Grade three or higher adverse events included neutropenia, liver enzyme elevation, oral mucositis, anemia, and diarrhea.", "population_specificity": "Patients aged \u226580 years with stage III colorectal cancer who underwent curative resection.", "effective_dosage": "UFT 300 mg/m\u00b2 and leucovorin (LV) dosage not specified.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:02.430929+00:00"}
{"study_id": 102632, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and efficacy of BI 456906 (a GCGR/GLP-1R dual agonist) in reducing body weight and its effects on plasma alanine levels in Japanese men with overweight/obesity.", "results_summary": "BI 456906 reduced plasma alanine levels, indicating indirect target engagement at GCGRs and GLP-1Rs. It also significantly decreased placebo-corrected body weight by up to 12.37% after 16 weeks, though adverse events like decreased appetite led to withdrawals in some participants.", "population_specificity": "Healthy Japanese men with a BMI of 23 to 40 kg/m\u00b2.", "effective_dosage": "1.8 mg once weekly (DG 1), 4.8 mg once weekly (DG 2), and 2.4 mg twice weekly (DG 3).", "study_duration": "16 weeks.", "interactions": "Transient delayed gastric emptying (observed via reduced paracetamol absorption).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:02.732093+00:00"}
{"study_id": 102636, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the incidence of statin-associated muscle symptoms (SAMS) in elderly patients with ASCVD receiving intensive statin monotherapy versus combination therapy, including monitoring alanine transaminase levels as a secondary endpoint.", "results_summary": "The abstract does not report specific results regarding alanine transaminase levels or Alanine's effects, as the study primarily focused on SAMS and LDL-cholesterol outcomes.", "population_specificity": "Elderly patients (70 years or older) with established atherosclerotic cardiovascular disease (ASCVD).", "effective_dosage": "Not specified for Alanine (study used rosuvastatin 20 mg or rosuvastatin/ezetimibe 5/10 mg).", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:06.835795+00:00"}
{"study_id": 102637, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of SGLT2 inhibitors and TZDs on liver enzymes (including alanine aminotransferase, ALT), steatosis, and fibrosis in patients with NAFLD, with or without T2DM.", "results_summary": "Both SGLT2 inhibitors and TZDs showed equivalent, non-significant improvements in ALT, AST, GGT, hepatic fibrosis, and other metabolic markers. SGLT2 inhibitors significantly reduced visceral fat area and body weight compared to TZDs.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD), with or without type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:07.681551+00:00"}
{"study_id": 102639, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to highlight the role of LC-MS/MS in identifying protein biomarkers, including Alanine transaminase, for early detection and monitoring of COVID-19 severity.", "results_summary": "The abstract mentions Alanine transaminase as a clinically significant protein biomarker in COVID-19, analyzed by LC-MS/MS, but does not provide specific results regarding its effects or outcomes.", "population_specificity": "COVID-19 patients (specific demographics not detailed).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:07.706602+00:00"}
{"study_id": 102638, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the prognostic impact of serum biomarkers, including the De Ritis ratio (aspartate aminotransferase/alanine transaminase), in patients with resected atypical meningiomas.", "results_summary": "The study found that a postoperative De Ritis ratio >2 was associated with higher progression/recurrence rates in atypical meningioma patients, particularly those not treated with adjuvant radiation therapy. Alanine transaminase was part of this ratio but not independently analyzed for efficacy.", "population_specificity": "523 patients with resected intracranial atypical meningiomas from 5 Asian institutions.", "effective_dosage": "Not specified", "study_duration": "Serum data were collected within 1 week after surgery; long-term follow-up duration not specified.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:10.610554+00:00"}
{"study_id": 102642, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety and efficacy of concurrent pembrolizumab with AVD (including dacarbazine, which metabolizes to alanine) in untreated classic Hodgkin lymphoma.", "results_summary": "The study found that grade 3 or 4 immune-related adverse events, including alanine aminotransferase elevation, occurred in 3 patients, but the combination showed promising safety and efficacy overall.", "population_specificity": "30 patients with untreated classic Hodgkin lymphoma.", "effective_dosage": "Not specified for alanine.", "study_duration": "Median follow-up of 2.1 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:11.590365+00:00"}
{"study_id": 102640, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare peri-operative and long-term survival outcomes between minimally invasive liver resection (MILR) and open liver resection (OLR) in patients with hepatocellular carcinoma (HCC), not specifically to evaluate Alanine.", "results_summary": "The study found that MILR resulted in less blood loss, fewer blood transfusions, lower post-operative complications, and shorter hospital stays compared to OLR, with comparable survival outcomes. Alanine transferase (ALT) levels were matched between groups but were not a primary focus of the study.", "population_specificity": "Patients with hepatocellular carcinoma (HCC) who underwent liver resection.", "effective_dosage": "Not available", "study_duration": "Not applicable (study compared surgical outcomes, not an intervention involving Alanine)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:12.889442+00:00"}
{"study_id": 102641, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of therapeutics, including brincidofovir, for mpox treatment, noting potential liver injury indicated by raised alanine aminotransferase (ALT) levels.", "results_summary": "The study found very low-certainty evidence suggesting brincidofovir may cause mild liver injury (raised ALT levels) in mpox patients, but no severe drug-induced liver injury was reported. Alanine itself was not directly studied for safety or efficacy.", "population_specificity": "Humans with mpox infection, including those at risk of severe disease.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:13.582275+00:00"}
{"study_id": 102643, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the impact of lifestyle optimization (including diet and exercise) on liver regeneration and outcomes in live liver donors, with a focus on markers like Alanine transaminase.", "results_summary": "The intervention group showed significantly lower Alanine transaminase levels, reduced steatosis, and improved liver regeneration compared to the control group. These changes were associated with better outcomes in both donors and recipients.", "population_specificity": "Live liver donors (LLDs) with no or minimal steatosis.", "effective_dosage": "Not specified (customized low-calorie diet matching basal requirements).", "study_duration": "2 weeks before surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:14.551730+00:00"}
{"study_id": 102644, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy of empagliflozin versus placebo in treating non-alcoholic fatty liver disease, including its effects on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that empagliflozin treatment showed no significant improvement in ALT levels, hepatic steatosis, liver stiffness, or other metabolic markers compared to placebo, suggesting it may not be effective for non-alcoholic fatty liver disease.", "population_specificity": "Patients with non-alcoholic fatty liver disease (212 participants across three RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:16.188022+00:00"}
{"study_id": 102646, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic agents, including the impact on alanine aminotransferase levels as an adverse event.", "results_summary": "The study found that increased alanine aminotransferase (22%) was a common adverse event of the triple therapy, but the abstract does not specifically evaluate alanine's efficacy or safety as a supplement.", "population_specificity": "Patients with solid cancers receiving PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic agents.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:17.940736+00:00"}
{"study_id": 102645, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of curcumin supplementation, alone or combined with non-pharmacological therapies, in improving metabolic and liver health markers, including alanine aminotransferase (ALT), in individuals with MAFLD.", "results_summary": "The study found that curcumin supplementation, with or without lifestyle changes, led to statistically significant improvements in ALT, AST, FBI, HOMA-IR, TG, TC, and WC, suggesting potential benefits for MAFLD management. However, the authors noted the need for more rigorous studies to confirm these findings.", "population_specificity": "Individuals with metabolic (dysfunction)-associated fatty liver disease (MAFLD), often accompanied by obesity, diabetes, pre-diabetes, or hypertension.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:18.678690+00:00"}
{"study_id": 102647, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical efficacy of supplementing qi dispelling wind and activating blood circulation methods, including their impact on alanine transaminase levels, in patients with IgA nephropathy.", "results_summary": "The study found that the treatment method did not impact normal levels of alanine transaminase, suggesting no adverse effects on liver function, while significantly improving renal function and reducing 24-hour urinary protein levels in IgAN patients.", "population_specificity": "Patients with IgA nephropathy (IgAN).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:19.771137+00:00"}
{"study_id": 102648, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks in postmenopausal women with vasomotor symptoms.", "results_summary": "The study found that fezolinetant was generally safe and well-tolerated, with similar rates of adverse events across placebo and treatment groups. Endometrial hyperplasia and malignancy rates were low, and changes in bone mineral density and trabecular bone score were similar across groups.", "population_specificity": "Postmenopausal women seeking treatment for vasomotor symptoms associated with menopause.", "effective_dosage": "30 mg and 45 mg once daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:21.759440+00:00"}
{"study_id": 102650, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the survival benefits of combining sintilimab, apatinib, and chemotherapy in patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer, not specifically focusing on Alanine.", "results_summary": "The study found elevated alanine aminotransferase as one of the grade 3-4 adverse events, but the primary focus was on the combination therapy's anti-tumor activity and safety, not Alanine's effects.", "population_specificity": "Patients with previously treated advanced gastric or GEJ adenocarcinoma.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Until disease progression, intolerable toxicity, or withdrawal of consent.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:23.579030+00:00"}
{"study_id": 102649, "supplement_id": 863, "safety_score": "70", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and management of treatment-related adverse events (TRAEs) associated with adagrasib, including hepatic toxicities like increased alanine aminotransferase/aspartate aminotransferase.", "results_summary": "The study found that adagrasib-related TRAEs, including hepatic toxicities (elevated alanine aminotransferase/aspartate aminotransferase), were generally mild to moderate, manageable with interventions, and resulted in low treatment discontinuation rates. Gastrointestinal toxicities and fatigue were also common but could be mitigated with dose adjustments, dietary changes, and supportive medications.", "population_specificity": "Patients with KRASG12C-mutated solid tumors, including those with CNS metastases.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:24.481769+00:00"}
{"study_id": 102651, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between food restriction and liver enzyme levels, including alanine transferase (ALT), to determine if dietary restriction improves these markers.", "results_summary": "The meta-analysis found that food restriction reduced ALT levels (SMD -0.36) and GGT levels (SMD -0.23), with AST levels decreasing in medium-term interventions (SMD -0.48). The results suggest dietary restriction may improve liver enzyme levels in adults.", "population_specificity": "Adults (1982 participants across 17 trials)", "effective_dosage": "Not specified", "study_duration": "Varied, with medium-term interventions defined as 5 weeks to 6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:24.748320+00:00"}
{"study_id": 102652, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not studying Alanine; the study focused on tafolecimab, a PCSK9 monoclonal antibody, for treating heterozygous familial hypercholesterolemia (HeFH).", "results_summary": "The study did not investigate Alanine; it found that tafolecimab significantly reduced LDL-C levels in Chinese patients with HeFH.", "population_specificity": "Chinese patients with heterozygous familial hypercholesterolemia (HeFH).", "effective_dosage": "Not applicable (study did not involve Alanine).", "study_duration": "12-week double-blind treatment period followed by 12-week open-label extension.", "interactions": "None mentioned (study did not involve Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:26.538754+00:00"}
{"study_id": 102653, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced NSCLC patients.", "results_summary": "Iruplinalkib demonstrated favorable efficacy with an IRC-assessed ORR of 69.9% and DCR of 96.6%, along with manageable safety profiles, though common TRAEs included increased alanine aminotransferase (37.0%).", "population_specificity": "ALK-positive crizotinib-resistant advanced NSCLC patients aged \u226518 years with ECOG performance status of 0-2.", "effective_dosage": "180 mg orally once daily (with a 7-day lead-in phase at 60 mg once daily).", "study_duration": "Median follow-up time was 18.2 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:29.067546+00:00"}
{"study_id": 102655, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the association between liver injury (including alanine aminotransferase levels) and the severity of COVID-19.", "results_summary": "The study found that hepatocellular injury, including elevated alanine aminotransferase levels, was associated with severe COVID-19, suggesting liver injury could serve as a prognostic biomarker for disease severity.", "population_specificity": "Patients diagnosed with COVID-19 (28,663 participants across 46 studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:29.294816+00:00"}
{"study_id": 102654, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effects of liraglutide on type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD), including its impact on alanine aminotransferase levels.", "results_summary": "The study found that alanine aminotransferase levels were lower in the experimental group compared to the control group in 10 out of the selected studies, indicating a potential benefit of liraglutide. However, no significant difference in aspartate transaminase changes was observed between the two groups.", "population_specificity": "Patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:29.530725+00:00"}
{"study_id": 102656, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of alanine as a conventional biomarker in mitochondrial disease diagnosis and follow-up, alongside newer biomarkers like FGF21 and GDF15.", "results_summary": "The study found that alanine, along with lactate and pyruvate, is a conventional blood biomarker for mitochondrial diseases, but newer biomarkers like FGF21 and GDF15 outperform it in specificity and sensitivity for muscle-manifesting mitochondrial diseases. Alanine remains part of the diagnostic toolkit but is less effective than the newer metabokines.", "population_specificity": "Patients with mitochondrial diseases, particularly those with muscle-manifesting symptoms.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:31.558110+00:00"}
{"study_id": 102657, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to establish consensus guidelines for metabolic investigations, including the assessment of amino acids like Alanine, in diagnosing mitochondrial disorders.", "results_summary": "The study outlines diagnostic approaches and recommends evaluating amino acids in blood and urine as part of metabolic investigations for mitochondrial disorders, but does not specifically report on Alanine's effects.", "population_specificity": "Patients suspected of having mitochondrial disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:32.217416+00:00"}
{"study_id": 102658, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the association between higher alanine aminotransferase levels and the risk of NAFLD in persons with HIV (PWH).", "results_summary": "Higher alanine aminotransferase levels were independently associated with an increased risk of NAFLD in PWH, but the study did not focus on alanine supplementation or its direct effects.", "population_specificity": "Persons with HIV (PWH) in outpatient clinics across three US centers.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:33.283709+00:00"}
{"study_id": 102659, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the hepatotoxicity profile, spectrum, and safety ranking of immune checkpoint inhibitor drugs, including their effects on alanine aminotransferase levels.", "results_summary": "The study found that the programmed death ligand 1 inhibitor+targeted therapy drug+chemotherapy group had the highest risk of treatment-related increases in all-grade alanine aminotransferase levels. No significant difference in immune-related hepatotoxicity was found between PD-1 and CTLA-4 inhibitors for all-grade hepatotoxicity, but CTLA-4 inhibitors had a higher risk of grade 3-5 hepatotoxicity.", "population_specificity": "Cancer patients treated with immune checkpoint inhibitors (n=164,782).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:35.200036+00:00"}
{"study_id": 102660, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effect of curcumin + piperine on cardiometabolic risk factors, hepatic steatosis, and fibrosis in NAFLD patients with moderate-to-high hepatic steatosis.", "results_summary": "Curcumin + piperine improved waist circumference, blood pressure, lipid profile, blood glucose, and liver enzymes, but did not significantly affect fibroscan measurements as a marker of NAFLD improvement.", "population_specificity": "Patients diagnosed with moderate-to-high NAFLD by liver sonography.", "effective_dosage": "500 mg/day curcumin plus 5 mg/day piperine.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:36.897386+00:00"}
{"study_id": 102661, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of metformin and pioglitazone combined with vitamin E on liver enzymes (including alanine aminotransferase) and sonography grade in non-alcoholic fatty liver disease patients.", "results_summary": "Metformin combined with vitamin E significantly reduced alanine aminotransferase levels and improved sonography grade, while pioglitazone with vitamin E showed no significant changes in liver enzymes.", "population_specificity": "68 patients diagnosed with non-alcoholic fatty liver disease.", "effective_dosage": "800 IU vitamin E daily (all patients); 1000 mg metformin daily or 15 mg pioglitazone daily.", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:39.637084+00:00"}
{"study_id": 102664, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate whether a new nutraceutical supplement composition, including Alanine, could improve metabolic and endocrine parameters related to obesity.", "results_summary": "The study found reductions in waist circumference, waist-to-height ratio, waist-to-hip ratio, and improvements in biomarkers like AST/ALT ratio (a NAFLD indicator), cortisol, and TSH levels after supplementation.", "population_specificity": "Sedentary adults (women and men) with a BMI \u226434.9 kg/m\u00b2.", "effective_dosage": "Not specified", "study_duration": "180 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:40.621446+00:00"}
{"study_id": 102663, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and relative bioavailability of AXA1665, a fixed-ratio amino acid composition containing Alanine, compared to a standard protein supplement.", "results_summary": "The study found a dose-dependent increase in plasma AUC for AXA1665, indicating effective absorption, but did not report significant adverse effects. The pharmacokinetics and bioavailability of constituent AAs, including Alanine, were assessed across multiple dosages.", "population_specificity": "Healthy subjects (N = 16)", "effective_dosage": "4.9 g, 9.8 g, 19.6 g, 29.4 g, and 39.2 g of AXA1665; 35 g protein supplement (single doses)", "study_duration": "Single-dose administration in a crossover design", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:40.651787+00:00"}
{"study_id": 102662, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 96, "quality_score": 85, "study_goal": "The researchers aimed to assess the real-world efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese adolescents with chronic HCV infection, including its effects on serum alanine aminotransferase levels.", "results_summary": "The study found that G/P treatment significantly decreased serum alanine aminotransferase levels and achieved a 96% sustained virologic response rate (SVR12) with mostly mild adverse events and no serious effects on growth or maturation.", "population_specificity": "Japanese adolescents aged 12-17 years with chronic HCV infection.", "effective_dosage": "300 mg glecaprevir and 120 mg pibrentasvir once daily.", "study_duration": "8 or 12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:41.238184+00:00"}
{"study_id": 102667, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effect of a culturally tailored Patient Navigator-led Intervention on chronic hepatitis B monitoring and treatment adherence, including alanine aminotransferase (ALT) testing, among Asian Americans.", "results_summary": "The intervention group showed significantly higher rates of doctor visits and ALT testing compared to the control group at both 6-month and 12-month follow-ups, indicating improved adherence to monitoring and care.", "population_specificity": "Asian Americans with chronic hepatitis B in the greater Philadelphia and New York City metropolitan areas.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:42.194870+00:00"}
{"study_id": 102666, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of sotorasib, including its impact on alanine aminotransferase levels, compared to docetaxel in patients with advanced NSCLC and KRAS mutations.", "results_summary": "Sotorasib showed a statistically significant increase in progression-free survival compared to docetaxel, with a more favorable safety profile. Alanine aminotransferase increase was a common but manageable adverse event (8% grade 3 or worse).", "population_specificity": "Patients aged \u226518 years with advanced NSCLC and KRAS mutations.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median follow-up of 17.7 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:42.421355+00:00"}
{"study_id": 102668, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the impact of TACE and HAIC on liver function, including alanine transaminase levels, in HCC patients post-resection.", "results_summary": "The study found that TACE significantly increased alanine transaminase levels in the short term, while HAIC had a smaller impact. Long-term liver function was not significantly affected by either treatment.", "population_specificity": "138 hepatocellular carcinoma (HCC) patients post-resection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:44.000020+00:00"}
{"study_id": 102669, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the mechanism of Spleen-strengthening and liver-draining formula (SLF) against NAFLD, particularly its effects on glucolipid metabolism and intestinal flora.", "results_summary": "SLF improved liver function, reduced liver fat content, and enhanced glucolipid metabolism in NAFLD patients. It also modulated intestinal flora diversity and species abundance.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:45.688802+00:00"}
{"study_id": 102672, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were investigating the presence and implications of alanine in a brain abscess case caused by Parvimonas micra infection.", "results_summary": "Magnetic resonance spectroscopy detected a peak alanine concentration of 1.5 ppm in the brain abscess, but the study did not evaluate alanine's therapeutic or adverse effects. The focus was on diagnosing and treating the abscess, not alanine's role.", "population_specificity": "A 47-year-old woman with a brain abscess caused by Parvimonas micra infection.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:50.149804+00:00"}
{"study_id": 102671, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review long-term and real-world data on the tolerability, safety, and efficacy of lasmiditan, ubrogepant, and rimegepant for acute migraine treatment, including potential effects on alanine transaminase levels.", "results_summary": "The study found that increased alanine transaminase levels were observed in two cases possibly related to ubrogepant, but levels normalized despite continued use. No significant cardiovascular adverse events were linked to the medications.", "population_specificity": "Patients with chronic migraine, including those with comorbidities, cardiovascular diseases, and polypharmacy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:50.562076+00:00"}
{"study_id": 102674, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether alanine mediates the causal association between lower birthweight and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that alanine partially mediates (10.01%) the effect of lower birthweight on NAFLD and has a unidirectional effect on insulin resistance.", "population_specificity": "Europeans (298,142 for birthweight GWAS; 8434 NAFLD cases and 770,180 controls for NAFLD GWAS).", "effective_dosage": "Not available", "study_duration": "Not applicable (Mendelian randomization study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:51.345064+00:00"}
{"study_id": 102670, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify metabolic biomarkers, including Alanine, related to poor ovarian response in older patients with kidney-qi deficiency and assess the efficacy of Guilu Erxian ointment in improving IVF outcomes.", "results_summary": "The study found that L-Alanine was closely related to older patients with poor ovarian response due to kidney-qi deficiency, suggesting it may serve as a biomarker. Guilu Erxian ointment improved IVF outcomes, potentially through amino acid and fatty acid metabolism regulation.", "population_specificity": "Older infertile patients with poor ovarian response of kidney-qi deficiency type undergoing IVF-ET.", "effective_dosage": "Not specified for Alanine; Guilu Erxian ointment was administered from the third day of menstruation until IVF surgery.", "study_duration": "From the third day of menstruation until IVF surgery (duration not explicitly stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:51.701139+00:00"}
{"study_id": 102673, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in children with cholestasis, including its effects on serum alanine aminotransferase levels.", "results_summary": "UDCA improved symptoms of cholestasis in children and reduced serum levels of alanine aminotransferase, total bilirubin, direct bilirubin, and total bile acid. Adverse drug reactions were primarily gastrointestinal, with no significant difference in incidence compared to placebo/blank control groups.", "population_specificity": "Children with cholestasis", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:51.897542+00:00"}
